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Hearing loss is the most common sensory disorder and despite the identification of over 
143 genes, many loci remain unsolved. Therefore, the identification of novel genes are of great 
importance to provide insight into disease pathways and improve the diagnosis and 
management of hearing loss. Due to a limited gene pool, genetic isolates, such as the island of 
Newfoundland, provide unprecedented opportunities for gene discovery. The objective of this 
thesis was to identify the genetic basis of hearing loss in several large Newfoundland families 
with either autosomal recessive or dominant hearing loss. Firstly, we identified a 
pathognomonic deafness, autosomal recessive 29 (DFNB29; OMIM: 614035) phenotype that 
was caused by a novel pathogenic CLDN14 missense variant, which resided on a 1.4 Mb 
ancestral haplotype across four families. Even though DFNB29 is associated with a highly 
variable, congenital phenotype, we observe cases of prelingual hearing loss that progresses to a 
distinct audioprofile. Subsequently, we identified a linked region (13q34; LOD: 4.77) within a 
large autosomal dominant hearing loss family that led to the discovery of a pathogenic splicing 
variant in a nascent ATP11A exon, which activates a cryptic splice site 153 bp downstream of 
the canonical splice site. This linked region overlaps with the DFNA33 locus, and hearing loss 
due to ATP11A exhibits significant variable expressivity, which is consistent with the family 
from Germany used to map this locus. Unexpectedly, three families were found to have Usher 
syndrome, caused by homozygous or compound heterozygous USH2A splicing variants that co-
segregated in two families that were initially ascertained as non-syndromic retinitis pigmentosa, 
while the remaining non-syndromic hearing loss family was positive for a novel pathogenic 
ADGRV1 nonsense variant. Given that these families were reassigned to an Usher syndrome 
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diagnosis based on genetic testing, this highlights the importance of employing next-generation 
sequencing in the clinical setting. In summary, this thesis identified a novel autosomal 
dominant hearing loss gene, and reclassified four variants of unknown significance to 
pathogenic variants, ascertaining the genetic etiology of deafness within eight families in the 
Newfoundland genetic isolate. These discoveries accelerate the diagnosis and surveillance of 
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Chapter 1: General Introduction 
1.1 The Human Genome and Genomic Variation 
Our understanding of genetics and the human genome has undergone many 
transformations in recent history. In a very short period of time, the field has discovered the 
structure of DNA, described the Central Dogma of Molecular Biology, mapped the entire 
human genome, and identified millions of variants across the genome. This rapid development 
of genomics has led to unprecedented improvements in the diagnosis, surveillance, and 
treatment of many human conditions. Moreover, the advent of advanced next-generation 
sequencing (NGS) technologies has broadened our understanding of molecular biology at both 
the DNA and RNA levels.   
 
1.1.1 Features of the Human Genome 
The human genome is approximately 3 billion nucleotides in length; however, mapping 
the human genome is not entirely complete(Green et al., 2015). Several multi-megabase (Mb) 
sized gaps within the telomeres and centromeres of most chromosomes are challenging to 
sequence and assemble due to the repetitive nature of these regions and extreme sequence 
homogeneity(Miga, 2015). The initial draft of the Human Genome Project suggested that there 
were 30,000 – 40, 000 protein coding genes(Lander et al., 2001). However, more recent 
investigations suggest as little as 19,000 genes, representing 1 – 2% of the entire 
genome(Ezkurdia et al., 2014). The other 99% of the genome is non-coding, and despite being 
initially referred to as  “junk DNA”(S. Ohno, 1972), massive efforts such as the Encyclopedia 
of DNA Elements (ENCODE) project have described hundreds of thousands of functional 
regions that have significant roles in regulating gene expression(ENCODE, 2012). For 
 2 
example, gene expression can be regulated through the epigenetic modification of non-coding 
regulatory regions, such as the methylation of distal gene enhancers and repressors, as well as 
CpG islands within promoter regions(Blattler & Farnham, 2013). Moreover, DNA 
methylation(Lev Maor et al., 2015), non-coding RNA genes(Romero-Barrios et al., 2018) and 
retrotransposons(Belancio et al., 2006) have also been shown to regulate key processes, such as 
alternative RNA splicing. 
 
1.1.2 An Overview of RNA Splicing  
Even though the number of coding genes is much lower than once thought, more recent 
RNA studies have identified approximately 205,000 protein-coding transcripts and this number 
continues to grow(Hu et al., 2015). Our understanding of the human genome is relatively 
complete; however, the same cannot be said at the RNA or whole transcriptome level. 
Alternative splicing is a tightly regulated process that increases protein biodiversity in an 
estimated 95% of all multiexon genes(Pan et al., 2008). This crucial mechanism produces many 
different mRNA transcripts with different combinations of exons, enabling cell potency and the 
terminal differentiation of stem cells that are committed to a particular function in the body. 
With the exception of the testis and brain, isoform-specific gene expression explains 45% and 
85% of the variance between individuals and tissues, respectively, and fewer than 200 genes are 
tissue-specific(Mele et al., 2015).  
Immediately after transcription, immature mRNA is spliced through a highly regulated 
and complex process that removes intronic sequences and ligates exons together, producing a 
mature mRNA (reviewed in Tom Strachan, 2010). This process is mediated by the spliceosome, 
a multimeric complex comprised of small nuclear ribonucleoprotein (snRNP; U) subunits. Each 
 3 
snRNP contains a small nuclear RNA (snRNA) and proteins. Consensus sequences are required 
at the exon-intron boundaries for an intron to be removed by the spliceosome. Among these 
requirements are a G at the 5’ end of the exon and GU at the 3’ end of the intron, which denotes 
a donor site (also referred to as the 5’ splice site). The consensus sequence marking an acceptor 
site (or 3’ splice site) is comprised of an AG at the 3’ end of the intron, as well as a G at the 5’ 
end of the exon. A branch site that contains an adenosine toward the middle of the intron is also 
required for the removal of introns (Figure 1.1a). The first step of RNA splicing is the binding 
of the U1 snRNP to the donor splice site, followed by binding of the U2 snRNP to the branch 
site (Figure 1.1b). Next, the trimer of U4, U5 and U6 snRNPs binds in the intron region, 
completing spliceosome assembly (Figure 1.1c). Subsequently, the donor site is cut and the 5’ 
end of the intron is ligated to the adenosine in the branch site to form a lariat structure (Figure 
1.1d). At this time, the U1 and U4 snRNPs disassociate (Figure 1.1d) from the spliceosome and 
the U6 and U5 snRNPs shift positions within the intronic sequence (Figure 1.1e). Finally, the 
U5 snRNP cuts the acceptor splice site and ligates the exons together – the lariat intron and 
remaining components of the spliceosome are then released (Figure 1.1f). 
The post-transcriptional regulation of immature mRNAs is quite complex. In addition to 
3’ polyadenylation and 5’-capping, immature mRNA molecules can be spliced in a variety of 
ways through alternative splicing, producing different mature mRNA that encode for different 
protein isoforms(Grabowski & Black, 2001; Kornblihtt et al., 2013; Figure 1.2). Most exons in 
genes can be included or excluded in the mature mRNA, or they can become shortened or 
lengthened by altering the position of constitutive exons 5’ or 3’ to splice sites (Figure 1.3; 




























Figure 1.1. Simplified Mechanism of RNA Splicing. a) immature single-stranded mRNA that 
contains the highly conserved 5’ GU and 3’ AG motifs required for RNA splicing and 
producing a mature mRNA molecule. b) The U1 and U2 snSRPs bind to the 5’ splice site and 
branch site, respectively, c) The U5-6 snSRPs are recruited to the spliceosome complex, d) the 
5’ intron is cleaved, producing a lariat structure, e) the U1 and U4 snSRPs dissociate, f) U2, U5 
and U6 reposition to cleave the 3’ end of the intron g). ssRNA: single-stranded RNA, G: 
Guanine, U: Uracil, A: Adenosine, U1-U6: snSRP 1-6. This file is licensed under the Creative 


























Figure 1.2. Three protein isoforms produced by alternative RNA splicing. a) Full-length dsDNA 
gene containing all possible coding exons, b) Immature mRNA molecule, c) Three different 
alternatively spliced transcripts that d) translate into three different protein isoforms. E: exon, i: 
intron, dsDNA: double-stranded DNA, ssRNA: single-stranded RNA, mRNA: messenger RNA. 
This file is licensed under the Creative Commons Attribution-Share Alike 4.0 International 
































Figure 1.3. Possible alternative splicing patterns and mechanisms. Blue boxes represent 
constitutive exons present in all final mRNAs. Patterned boxes represent cassette exons that 
may or may not be included in final transcript, depending on the cell or tissue type in question. 
a) An exon can be either included or skipped, b) Introns can be retained or excluded from the 
mature mRNA, c/d) Alternative 5’ donor or 3’ acceptor splice sites and shorten or lengthen any 
given exon, e) Alternative promoters and f) Alternative poly(A) sites can lengthen or shorten 
the size of a transcript, g) Adjacent exons can be mutually exclusive such that only one exon 
can be included in the final transcript. This file is licensed under the Creative Commons 
Attribution-Share Alike 4.0 International license, adapted from(Contributors12) 
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can be changed through the use of alternative 3’ terminal exons that alter polyadenylation sites, 
or alternative 5’ exons that switch to a different internal promoter within a given 
gene(Kornblihtt et al., 2013). Finally, some isoforms retain their introns and are considered as 
processed non-coding transcripts that are degraded by nonsense mediated decay, which do not 
produce a functional protein(Kim et al., 2007; Sugnet et al., 2004). These mechanisms serve a 
specific purpose for specific cells and tissues, and changing splice sites can drastically affect an 
encoded protein(Burke et al., 1992). For example, more minute changes can significantly 
impact protein localization, enzymatic activity, or increase or decrease ligand affinity for a 
receptor. Conversely, alternative splicing that excludes several exons can result in the lack of an 
entire functional domain in a protein(Burke et al., 1992; C. W. Smith & Nadal-Ginard, 1989).  
Mechanisms that regulate alternative splicing are largely controlled by specific cis-
regulatory sequence motifs that are divided into four main categories: intronic splicing silencers 
(ISSs), exonic splicing silencers (ESSs), intronic splicing enhancers (ISEs) and exonic splicing 
enhancers (ESEs). These cis-regulatory sequence motifs regulate alternative splicing through 
their interaction with two large families of trans-acting proteins: Ser/Arg-rich proteins (SRs) 
and heterogenous nuclear ribonuclear proteins (hnRNPs; Kornblihtt et al., 2013). This 
interaction targets critical components of the spliceosome complex by influencing the affinity 
of snRNPs at exon-intron boundaries; specifically, hnRNPs bind to ISEs and ISS and SRs 
interact with ESEs and ISEs to inhibit and promote RNA splicing, respectively(Kornblihtt et 
al., 2013; Figure 1.4). Together, these mechanisms highlight processes that drive diversity of 
terminally differentiated cells in living systems, given that gene expression profiles, including 











Figure 1.4. The Regulation and Mechanisms of Alternative Splicing. Many DNA elements that 
have proteins binding partners greatly influence which transcript is expressed in a cell. ESEs 
and ISEs interact with SRs to promote splicing. In contrast, hnRNPs bind to ISSs and ESSs to 
inhibit splicing. These cis-regulatory motifs and proteins regulate alternative splicing, promote 
protein biodiversity in a tissues, and permit terminal differentiation of cells from potent stem 
cells. Green arrow indicates a positive effect. Red, blunt ended lines indicate an inhibitory 
effect, ISS: intronic splicing silencers, ESS: exonic splicing silencers, ISE: intronic splicing 
enhancers ESE: exonic splicing enhancers. b-e) Black lines indicate splicing locations, SS: 
splice site, G: Guanine, U: Uracil, A: Adenosine, U1-U2: snSRP 1-2, SR: Ser/Arg-rich protein; 
shnRNPs: heterogenous nuclear ribonuclear proteins. This image is licensed under Creative 
















(Zhang et al., 2016). These basic principles apply to all eukaryotic systems – as cells commit to 
a specific lineage, gene expression and the number of protein isoforms increasingly become 
more diverse(Black, 2000).  
 
1.1.3 Cryptic and Alternative Splicing and Disease 
Genomic variants that result in aberrant RNA splicing can have significant impacts on 
human health.  The removal of intronic sequences from an immature RNA molecule is a tightly 
regulated process that is coordinated by highly conserved nucleotides at the exon-intron 
boundaries, as well as by recognition of these sequences by the spliceosome and additional 
auxiliary splicing factor proteins(Ward & Cooper, 2010). Therefore, variation within exon-
intron boundaries is generally not tolerated and is for the most part, pathogenic. The first two 
and last two nucleotides of an intron, which are GU and AG, respectively, are of particular 
importance for spliceosome recognition (Figure 1.1; Chen & Manley, 2009; K. Ohno et al., 
2018). Even though this “GU-AG rule of splicing” is important, variation in the last 2 
nucleotides of an exon and the first 6 nucleotides of an intron have a high likelihood of causing 
cryptic alternative splicing(Chen & Manley, 2009; K. Ohno et al., 2018). In addition to exon 
skipping and intron inclusion, such variants that reside within exon-intron boundaries can also 
activate a cryptic donor or acceptor splice site (Figure 1.5).  
Many state-of-the-art in silico algorithms, such as MaxEnt(Yeo & Burge, 2004), 
NNSPPLICE(Reese et al., 1997), SpliceSiteFinder(Desmet et al., 2009), and 
GeneSplicer(Pertea et al., 2001) help predict the pathogenicity of candidate splicing variants. 
While these in silico predictions have many advantages in that they are sensitive for detecting 










Figure 1.5. The Mechanisms of Cryptic Splicing. Variants that reside within exon-intron 
boundaries are likely to cause either: a) Cryptic exon skipping or inclusion, b) Cryptic intron 
retention, or they can activate a cryptic alternative donor splice site (c), or acceptor splice site 
(d). Blue boxes represent constitutive exons and pink boxes indicate cryptically spliced regions 
that are included in processed, mature mRNA. This image is licensed under Creative Commons 




consistently and accurately predict the specific slicing abnormality(Ernst et al., 2018). For 
example, a recent study(Baert et al., 2018) evaluated the performance of many in silico 
prediction tools and found that computational approaches were sensitive in detecting cryptic 
splicing effects in 21 BRCA1 and BRCA2 variants, but were unreliable in determining the 
specific splicing effect. Given these limitations, experimental validation of in silico predictions 
are essential to the interpretation of candidate splicing variants, and this is reflected in clinical 
variant interpretation guidelines, such as those published by the American College of Medical 
Genetics and Genomics (ACMG; Appendix A; Richards et al., 2015) and EuroGentest(Matthijs 
et al., 2016) . The pathogenicity of any given splicing variant is highly dependent on the 
sequence that is proximal to the exon-intron boundary. In the context of activating a cryptic 
donor or acceptor splice site, there is a 1/3 probability that this will create an in-frame insertion 
or deletion (INDEL). In light of the lack of specificity of in silico analyses, it is conceivable 
that candidate splicing variants that are predicted to cause exon skipping could experimentally 
validated as small, tolerated, in-frame insertions and deletions. This highlights the importance 
of studying candidate splicing variants at the RNA level.  
Not only does alternative splicing facilitate the terminal differentiation of tissue-specific 
somatic cells, this process is also implicated in pleiotropy, or the ability of a single gene to 
influence two or more unrelated phenotypic traits(Drivas et al., 2015) A recent survey of the 
human transcriptome identified that less than 200 genes are tissue specific(Mele et al., 2015). 
Given that there are in excess of 200,000 protein coding transcripts(Hu et al., 2015), genetic 
variants that reside in alternatively spliced, tissue-specific transcripts, could explain why 
different pathogenic variants in a single gene can cause both non-syndromic and syndromic 
Mendelian phenotypes(Dominguez et al., 2016). An excellent example that portrays the effects  
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of alternative splicing on pleiotropy is Tetratricopeptide Repeat Domain 8 (TTC8; MIM: 
608132) that is within the Bardet-Biedl syndrome 8 locus (BBS8; MIM: 615985). Pathogenic 
biallelic variants in TTC8 (NM_198309) cause Bardet-Biedl syndrome, an autosomal recessive 
condition characterized by overt clinical features, including developmental delay, obesity, 
postaxial polydactyly, hypogonadism and retinitis pigmentosa (RP; Ansley et al., 2003). 
However, Riazuddin et al (2010) identified a pathogenic splicing variant in a retinal-specific 
TTC8 transcript (NM_144596) that causes non-syndromic retinitis pigmentosa 51 (MIM: 
613464). Another such example of pleiotropy is the case of hereditary hearing loss and its 
syndromes. Until recently, pathogenic variants in collagen type XI alpha 1 chain (COL11A1), a 
gene that encodes an extracellular matrix protein, have been linked to connective tissue 
disorders that have hearing loss as a feature, such as Marshall syndrome (MIM: 154780; 
Annunen et al., 1999), Stickler syndrome type II (MIM: 604841; Majava et al., 2007; Rose et 
al., 2005), and fibrochondrogenesis (MIM: 228520; Tompson et al., 2010). Then Booth et al 
(2018) identified a pathogenic COL11A1 variant that causes exon skipping in an inner ear-
specific splicing transcript that maps to the deafness, autosomal dominant 37 hearing loss locus 
(DFNA37). In addition to having significant roles in the regulation of alternative 
splicing(Stower, 2013), non-coding regions of the genome also influence gene expression 
through microRNA (miRNA/miR)-mediated mechanisms(Gebert & MacRae, 2018). 
Even though every cell type in an individual human body contains a nearly identical 
copy of every gene across the genome, the regulation of gene expression at specific 
developmental time points permits terminal differentiation from multipotent to tissue-specific 
somatic cells. While gene expression can be regulated by many mechanisms, such as the 
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epigenetic modification of histones and CpG methylation, miRNA-mediated gene silencing 
exhibits a profound role during normal development(Gebert & MacRae, 2018). miRNAs are 
promiscuous molecules that can inactivate hundreds of mRNAs, regulating the spatiotemporal 
expression of genes(Gebert & MacRae, 2018). Like coding genes, miRNAs are transcribed by 
RNA polymerase II (Figure 1.6a); however, miRNAs can be derived from gene introns or from 
long non-coding RNAs (Berezikov, 2011; Lau et al., 2001). Upon transcription, miRNA 
biogenesis begins with the formation of primary miRNAs (pri-miRNAs), that contain a hairpin 
loop (Figure 1.6b; Gebert & MacRae, 2018). Before export to the cytoplasm, the RNase III 
enzyme, Drosha, and the DiGeorge syndrome critical region 8 (DGCR8) proteins complex with 
and cleave the pri-miRNA into a premature-miRNA (pre-miRNA) that is approximately 70 
nucleotides in length (Figure 1.6c; Nguyen et al., 2015; Nicholson, 2014). Subsequently, the 
pre-miRNA is carried out of the nucleus through a nuclear pore by the nuclear transporter, 
exportin-5 (Figure 1.6d; Okada et al., 2009). In the cytoplasm the pre-miRNA is recognized by 
a large RNase III protein called Dicer, which cleaves the hairpin loop, yielding a shorter (20-22 
nucleotide) double stranded mature miRNA (Figure 1.6e; Nicholson, 2014). Next, Argonaut-2 
(AGO2) interacts with Dicer to bind the pre-miRNA (Figure 1.6f). After unwinding and 
releasing the “passenger strand” (Figure 1.6g), the “guide strand” and AGO2 recruit several 
proteins to form the RNA-induce silencing complex (RISC; Figure 1.6h; Gebert & MacRae, 
2018). Thereafter, the RISC complex hybridizes and cleaves binding sites within the 3’ UTR of 
genes that are complementary to the seed sequence of the “guide strand” (Figure 1.6i; Bartel, 
2009), promoting translation repression and target mRNA degradation (Figure 1.6j). Thus, 
silencing the production of a functional protein (Jonas & Izaurralde, 2015). Like any other 





















Figure 1.6. Mechanisms of miRNA Biogenesis. a) miRNA gene is transcribed by RNA Pol II 
into a pri-miRNA (b) that is cleaved by Drosha and DGCR8 into a ~70 nucleotide pre-miRNA 
(c). The pre-miRNA is carried out the nucleus through a nuclear pore by exportin-5 (d), and is 
cleaved by Dicer, yielding a shorter (20-22 nucleotide) double stranded mature miRNA (e). The 
mature miRNA is loaded onto Argonaut-2 (f), which releases the passenger strand (g), and 
recruits accessory proteins to form the RISC complex (h). The RISC complex hybridizes and 
cleaves binding sites within the 3’ UTR of mRNAs that are complementary to the seed 
sequence of the guide strand (i), promoting translation repression and target mRNA degradation 
(j). miRNA: MicroRNA, Pol: Polymerase, DGCR8: DiGeorge syndrome critical region 8, pri-
miRNA: primary miRNA, pre-miRNA: premature miRNA, mRNA: messenger RNA, RISC: 
RNA-induce silencing complex, UTR: untranslated region, ORF: open-reading frame. This 
image is licensed under Creative Commons Attribution 4.0 International License, adapted 
from(Contributors3) 
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example, most miRNA genes harbour highly polymorphic regions in their 5’ and 3’  
ends, resulting in alternative splicing by Drosha and/or Dicer. Moreover, gene silencing is 
greatly dependant on the post-translational modification of proteins involved in miRNA 
biogenesis, such as the phosphorylation, PARylation and sumoylation of AGO2(Gebert & 
MacRae, 2019).  
In addition to normal development, miRNAs also have established roles in disease 
pathogenesis. For example, pathogenic variants in miR-96 (MIM: 611606) have been shown to 
cause autosomal dominant hearing loss (DFNA50; MIM: 613074). Given that these 
pathogenic variants reside within the seed sequence of miR-96, the processed guide strand 
within the RISC complex fails to hybridize to mRNA targets, leading to aberrant gene 
expression profiles within sensory hair cells that are required for normal auditory 
function(Mencia et al., 2009). This remarkable finding prompted a paradigm shift in hearing 
loss gene discovery efforts, revealing that many other miRNAs, including miR-182 and miR-
183, are involved in the normal development of the auditory system, as well as hearing 
loss(Ushakov et al., 2013). However, identifying miRNA-mediated hearing loss variants is not 
trivial, given that this mechanism involves many small cumulative events, rather than a single 
pathogenic variant(Rudnicki & Avraham, 2012). Conversely, this complexity is further 
confounded by variants that reside within miRNA binding sites(Ushakov et al., 2013). 
Nonetheless, with respect to a ubiquitously expressed gene that is associated with a syndromic 
disease, a variant that introduces a tissue-specific miRNA binding site into the 3’ UTR of that 
gene could theoretically result in a related but non-syndromic disorder(Ushakov et al., 2013). 
Even though variants that reside in miRNA genes themselves are not a common cause of 
hearing loss(Hildebrand et al., 2010), those variants within 3’ UTR miRNA binding sites 
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represents a promising area of research in human disease. Collectively, variation at the RNA 
level, including our understanding of alternative splicing, cryptic splicing, and the miRNA-
mediated spatiotemporal regulation of gene expression, represents a new, yet challenging area 
in human genetics that may uncover novel genes that have previously evaded discovery. 
 
1.2 Hereditary Hearing Loss and Its Syndromes 
1.2.1 The Auditory System and Hearing Loss  
The auditory system has a single, yet complex task – to relay external acoustic stimuli to 
the auditory cortex, where it is perceived as sound (J. Anthony Seikel, 2015).  Auditory 
perception begins with sound waves traveling into the outer ear and through the auditory canal 
where they meet and vibrate the tympanic membrane (or ear drum). The tympanic membrane is 
a cone-shaped structure that articulates with a chain of three small bones in the middle ear, 
consisting of the malleus, incus and stapes, which are collectively called the “auditory 
ossicles”. Auditory information of frequency and amplitude is passed on to the auditory system 
through vibration transfer from the footplate of the stapes to the oval window of the “bony 
labyrinth”. This labyrinth is filled with a sodium-rich fluid called perilymph. The round 
window is another flexible membrane, which permits the displacements of perilymph by the 
piston-like action of the stapes. The round window is found on the spiral portion of the bony 
labyrinth, known as the cochlea, which is the main sensory organ of the auditory system. 
(Figure 1.7). 
Vibrations produced by the stapes first enter and ascend to the apex of the cochlea 
through the scala vestibuli, which in turn, descend back down the cochlea through the scala 




Figure 1.7. Schematic of the auditory pathway. Acoustic stimuli enter the auditory system in the 
outer ear, where sound waves with travel through the auditory canal until this energy is 
absorbed by the tympanic membrane (or ear drum). This energy is then transferred to the 
auditory ossicles of the middle ear, the malleus, incus and stapes. The cochlea is a snail-shaped, 
fluid-dilled sensory organ within the auditory system. The cochlear fluid (or perilymph) is 
displaced by piston-like action of the stapes on the oval window. This mechanism is possible 
due to an additional flexible membrane called  the round window. Once incoming sound 
vibrations enter the cochlea, they elicit action potentials within sensory hair cells in the Organ 
of Corti, which in turn release neurotransmitters onto the auditory nerve that send electrical 
impulses to the brain. This image is licensed under Creative Commons Attribution 4.0 
International License, adapted from(Contributors4) 
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contains potassium-rich endolymph and is situated between the scala vestibuli and scala 
tympani. Together, differential electrochemical gradients between the three cochlear 
compartments are maintained and separated by two flexible membranes that move in response 
to the vibrations traveling up the scala vestibuli; namely, the Reissner’s membrane and the 
basilar membrane. The Organ of Corti is a highly specialized structure that is comprised of 
three rows of outer hair cells, a single row of inner hair cells, and additional supporting cells 
that collectively rest on the basilar membrane of the cochlear duct. This structure is filled with 
cortilymph, a perilymph-like medium that is sodium-rich and potassium-devoid. Despite the 
stark ionic composition differences between endolymph and cortilymph, the reticular lamina, 
which is comprised of tight junctions, creates a barrier between these two mediums and 
maintains these electrochemical gradients (Figure 1.8).  
The cochlea exhibits tonotopic organization, meaning that high and low frequency 
sounds are received at the base and apex of the cochlea, respectively, providing a frequency-
based map of the cochlea (Figure 1.9). In light of tonotopic organization, different frequencies 
peak at different positions along the basilar membrane, exciting distinctive subsets of hair cells. 
The manner in which the basilar membrane vibrates in response to sound is essential in our 
understanding of cochlear function.  Sensory hair cells within the Organ of Corti are located 
between the basilar and tectorial membranes and are stimulated by incoming sound vibrations 
(Figure 1.8). While the stereocilia that protrude from the apical surfaces of inner hair cells 
detect and transmit this auditory information to the brain through the cochlear nerve in response 
to fluid motion, those of the outer hair cells are directly coupled to the tectorial membrane and 
amplify incoming sound vibrations. In response to incoming vibrations into the cochlea, outer 















Figure 1.8. Anatomy and physiology of the cochlea. ) Schematic of the cochlea, indicating the 
cross sectional plane (dashed red line) that is depicted in (b). The three main compartments of 
the cochlea are the scala vestibuli and scala tympani (filled with sodium-rich perilymph), as 
well as the scala median (filled with potassium-rich endolymph). These compartments are 
separated by the Reissner’s and basilar membranes. The Organ of Corti contains three rows of 
outer hair cells and a single row of inner hairs, and resides on the basilar membrane. The Organ 
of Corti is also bathed in a perilymph-like fluid that is sodium rich. The endolymphatic and 
cortilymphatic electrochemical gradients are maintained by the reticular lamina (green dashed 
line). Tight junctions (c) at the apical surface of the Organ of Corti provide a barrier that 
prevents the mixing of endolymph and cortilymph. This image is licensed under Creative 


















Figure 1.9. Tonotopic map of the cochlea. This topological schematic of the cochlea 
demonstrates that the sensory hair cells at the base of the cochlea are responsible higher 
frequency sound perception, which decreases in frequency as you ascend to the apex of the 
cochlea. Human hearing frequencies range from 20kHz to 200 Hz. Hz: hertz, kHz: kilohertz (1 
kHz = 1,000 Hz). This image is licensed under Creative Commons Attribution 4.0 International 
License, adapted from(Contributors7) 
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auditory information to the brain through the cochlear nerve. These processes are mediated 
through mechanotransduction of sensory hair cells in the cochlea. A defining feature of 
auditory hair cells is that they occur in bundles that are mechanically linked to one another at 
the tip (tip links), and at the base (ankle links). While the major molecular constituents of ankle 
links include adhesion g-protein-coupled receptor-v1 (ADGRV1) and usherin (USH2A), tip 
links are comprised of protocadherin-15 (PCDH15) and cadherin-23 (CDH23). These adhesion 
proteins complex with scaffolding molecules, including myosins, which are bound to actin 
filament networks of the stereocilia (Figure 1.10a). Moreover, tip links complex with non-
specific, mechanically-gated ion channels, such as transmembrane channel-like protein 1 
(TMC1) and transmembrane channel-like protein 2 (TMC2) at the apical tips of stereocilia. 
Given that stereocilia are tethered together, stereocilia bundles deflect as a single unit in 
response to sound stimuli. This deflection creates tension between the tips links, which opens 
the mechanically gated ion channels (Figure 1.10b). Subsequently, sensory hair cells are subject 
to a massive influx of potassium and calcium, which depolarizes the cell (Figure 1.10c). Once 
the membrane potential of the sensory hair cell reaches threshold, an action potential will be 
produced, resulting the release of neurotransmitters onto the auditory nerve. The genes that 
encode for such ion channels, and adhesion and scaffolding proteins that comprise the tip and 
ankle links, are essential for maintaining normal hearing and many of them have been 
implicated in hereditary hearing loss and it syndromes (Appendix B).  
Hearing loss is one of the most common sensory disorders that affects an estimated 2-3 
in 500 newborns annually(Helga V Toriello 2016; Richard JH Smith, 1999 ). According to a 
hearing loss survey in 2006(Statistics Canada, 2010), 5% of Canadians aged 15 and over 















Figure 1.10. Schematic of hair cell bundles and mechanotransduction. A)  Hair cell bundle 
illustrating the presence of tip links and ankle links. The main molecular constituents of tip 
links include protocadherin-15 (PCDH15) and cadherin-23 (CDH23), which tether the apical 
surface of one stereocilia to the side of the adjacent stereocilia. Ankle links are comprised of 
other adhesion proteins; namely, adhesion g-protein-coupled receptor-v1 (ADGRV1) and 
usherin (USH2A). Together, these adhesion proteins bind with the stereocilia actin filament 
networks, through their interaction with myosin scaffolding complexes. B) Upon the arrival of a 
sound stimulus, hair cell stereocilia will deflect and create tension on the tip and ankle links, c) 
This tension permits the opening of mechanically gated ion channels, which will allow for ion 
such as potassium and calcium to enter the cell body of sensory hair cells. In turn, this 
depolarizes the cell, leading to potentials and the release of neurotransmitters to the auditory 
nerve This image is licensed under Creative Commons Attribution 4.0 International License, 
adapted from(Contributors8) 
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form of hearing loss(World Health Organization, 2018). Moreover, this overwhelming figure is 
projected to reach nearly 1 billion hearing impaired people by 2020(Van Eyken et al., 2007). 
There are four main types of hearing loss: conductive, sensorineural, mixed and central auditory 
dysfunction(Richard JH Smith, 1999). While conductive hearing loss involves obstruction of 
sound waves in reaching the inner ear through abnormalities of the outer or middle ear, 
sensorineural hearing loss is caused by deficits in the auditory nerve or inner ear. The 
combination of both sensorineural and conductive hearing loss is referred to as mixed hearing 
loss. Central auditory dysfunction is different from sensorineural and conductive hearing loss in 
that it involves defects in the central nervous system, which prevent the transmission and 
processing of auditory information (Richard JH Smith, 1999 ; Van Camp G, 2015).The 
identification, diagnosis, and treatment of hearing and balance disorders falls within the field of 
clinical audiology(Gelfand, 2011). In order to assess a patients level of hearing, balance and 
speech perception, audiologists rely on several behavioural exams, from a sound and 
psychological perspective.  
The key to understanding sound transmission is vibration (reviewed in Martin & Clark, 
2014). When somebody speaks, their vocal chords vibrate, producing pressure waves that are 
propagated through the air. Collectively, sound waves consist of two main components: 
compressions and rarefactions. While nitrogen and oxygen molecules in the air are pushed 
together by high pressure during the compression phase of a sound wave, rarefactions pull them 
apart in areas of low pressure. Sound frequency, measured in hertz (Hz), is defined as the 
number of sound waves that pass a certain point in a given time. High frequency sounds are 
produced by shorter waves that move more quickly through the air. In contrast, low frequency 
sounds result from fewer, slower fluctuating waves. The “loudness” of a sound is dependent on 
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amplitude, or the difference between the compression and rarefaction phases of a sound wave, 
which is measured in a relative, logarithmic unit called decibels (dB). 
Pure-tone audiometry measures hearing sensitivity by determining the lowest detectable 
sound amplitude at different frequencies. Specifically, this method measures air conduction 
hearing thresholds that range from 125 Hz to 8 kilohertz (kHz), which are the frequencies that 
are relevant to human speech. Pure tones are played through head phones to a maximal 
intensity (120 dB), until the subject indicates that they have heard the sound. Hearing 
thresholds are measured in both ears and are plotted on a behavioural audiogram, with the 
different tested frequencies on the X-axis and the sound amplitude (or intensity) on the Y-axis.  
On a standard audiogram, the left and right ears are annotated as X’s and O’s, respectively, and 
normal hearing is defined as having less than 20 dB hearing threshold across all frequencies. 
Mild hearing loss has hearing thresholds between 20-40dB. Moderate hearing loss has hearing 
thresholds between 41-70 dB. Severe hearing loss has hearing thresholds between 71-95 dB. 
Profound hearing loss has hearing thresholds in the excess of 95 dB (Figure 1.11). Audiogram 
configuration is typically classified into low, mid, and high frequencies. In addition, these 
configurations can be further characterized according to their slope as flat, gentle or steep, 
which can be present in one ear (unilateral), or more commonly, both ears (Mazzoli M, 2003; 
bilateral; Figure 1.12).  
 
1.2.2 The Genetics of Hearing Loss  
Given the wide-range hearing loss aetiologies that include aging, ototoxic drugs, noise 
exposure, and genetics, this disorder exhibits extreme heterogeneity in the clinical 













Figure 1.11. Audiogram demonstrating hearing loss severity. Normal hearing thresholds are 
characterized by the detection of sound above 20 dB at any frequency. Mild and moderate 
hearing loss thresholds range from 20-40 dB and 41-70 dB, respectively. While severe hearing 
loss demonstrates thresholds between 41-95 dB, a profound hearing loss is described as having 























Figure 1.12. Various audiograms illustrating the types of sensorineural hearing loss. A) normal 
hearing, b) Flat hearing loss, c) Gently sloping hearing loss, d) Steeply sloping, e) Precipitous 
hearing loss, f) Low-frequency ascending (reverse slope), g) Mid frequency “cookie-bite” and 




hearing loss is due to genetic factors(Morton & Nance, 2006), representing an unprecedented 
opportunity to identify and describe its molecular pathophysiology. However, phenocopies, or 
individuals that develop a given trait due environmental factors, are quite common in hearing 
loss(Arnett et al., 2011). For this reason, phenocopies may resemble other study subjects within 
larger families members with genetically-defined hearing loss. Thus, it cannot be understated 
how important it is to have a complete and thorough understanding of the hearing phenotype 
when performing genetic hearing loss studies. For the most part, hearing loss is a monogenic 
disorder caused by a single gene pathogenic variant(Richard JH Smith, 1999); however, 
multifactorial forms exist where both gene-gene and gene-environment interactions 
significantly influence the development and progression of hearing loss(Cui et al., 2017; Haider 
et al., 2002; Sherry et al., 2001; Speicher et al., 2009) 
In excess of 400 genetic syndromes involving deficits of the eye, neurological, kidney 
and musculoskeletal systems exhibit a hearing component(Helga V Toriello 2016). While non-
syndromic hearing loss accounts for 70% of hereditary hearing loss, the remaining 30% is 
recognized as syndromic and is the most common feature of multi-organ disorders(Richard JH 
Smith, 1999;  Toriello & Smith, 2013). Syndromic hearing loss is classically characterized by 
overt clinical features such as craniofacial and connective tissue abnormalities as in Treacher 
Collins syndrome. However, features of other hearing loss syndromes, such as visual deficits in 
Usher syndrome (USH), may manifest later in life, leading to delays or misdiagnosis(Keats & 
Corey, 1999; Kimberling et al., 2010; Mathur & Yang, 2015). This presents a significant 
challenge in the clinical management, diagnosis and surveillance of those at-risk of developing 
syndromic forms of hearing loss, given the high demand of prioritized genetic tests for 
disorders of known aetiologies. However, the development of synergistic relationships between 
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clinical and research teams is an effective approach of mitigating such diagnostic challenges. In 
addition, this approach accelerates the pace of gene discovery, as well as improving health care 
policy, ethics, and routine genetic testing(K. Hodgkinson et al., 2009). 
Tremendous progress has been made since the first description of a genetic form of 
hearing loss in 1995(de Kok et al., 1995). Specifically, a global effort in understanding the 
genetics of hereditary hearing loss and its syndromes has given rise to the identification of 
approximately 223 loci and 143 genes; thus, this disorder displays profound genetic 
heterogeneity(Van Camp G, 2015). Genetic loci that are associated with nonsyndromic hearing 
loss are designated as DFN (for DeaFNess), and these are further annotated according to their 
inheritance patterns: DFNA, DFNB, and DFNX loci categorically denote autosomal dominant, 
autosomal recessive, and X-linked inheritance, respectively(Richard JH Smith, 1999). Although 
an estimated 75-80% of  non-syndromic hearing loss is transmitted as an autosomal recessive 
trait, pathogenic variants that exhibit a dominant (20%), X-linked (2-5%) and mitochondrial 
(1%) inheritance pattern account for the remaining cases (Figure 1.13; R. J. Smith et al., 2005). 
Importantly, a significant number of these genes exhibit pleiotropy, where they are associated 
with both syndromic and nonsyndromic hearing loss –  the latter typically belonging to the 
DFNA and/or DFNB grouping. For example, MYO7A (MIM: 276903) can cause DFNA11 
(MIM: 601317) and DFNB2 (MIM: 600060), as well as USH1B (MIM: 276900)(X. Z. Liu, 
Walsh, Mburu, et al., 1997; X. Z. Liu, Walsh, Tamagawa, et al., 1997; Weil et al., 1995).  
Even though hearing loss is predominately expressed as a autosomal recessive trait, this 
may not reflect the true epidemiology of genetic hearing loss, due to factors such as 


















Figure 1.13. Prevalence of genetic hearing loss according to mode of inheritance. Data retrieved 
from Smith et al(R. J. Smith et al., 2005). 
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Despite how far the hearing loss research field has come, many loci remain unsolved(Richard 
JH Smith, 1999; Van Camp G, 2015). Among these unsolved loci, DFNA genes are particularly 
challenging to identify, given broad critical regions coupled with the rarity of large extended 
families with well-described clinical data. This problem is further exacerbated by reduced 
penetrance and variable expressivity of hearing phenotypes(Richard JH Smith, 1999) as well as 
over 10 million heterozygous genetic variants in human genome(Sherry et al., 2001). Variable 
expressivity refers to differing phenotypic features among individuals with the same genotype. 
For example, the recent discovery of PTPRQ (MIM: 603317) as the cause of DFNA73 
(Eisenberger et al., 2018) found extensive variable expressivity within a 4-generation German 
family. Specifically, a pathogenic nonsense variant co-segregated in this family; however, 
hearing loss onset ranged from early childhood to the third decade with a variable audiogram 
configuration(Eisenberger et al., 2018). Penetrance refers to the proportion of individuals 
carrying a particular genetic variant that express an associated phenotype. In cases of reduced 
penetrance, not all individuals with pathogenic alleles will display a given phenotype. For 
instance, a heterozygous, autosomal dominant, variant in GJB2, p.Val37Ile, is sufficient to 
cause DFNA3 (MIM: 601544) with an estimated 17% penetrance(Chai et al., 2015). These 
challenges highlight the importance of thorough clinical ascertainment and even though these 
factors present significant challenges in the discovery of dominant hearing loss genes, they can 
be overcome by studying large multiplex families, which are frequent within well-defined 
homogenous populations, such as the genetic isolate of Newfoundland.  
 
1.2.3 The Newfoundland Founder Population and Hearing Loss Research 
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 In recent history, the Newfoundland and Labrador (NL; island portion) population has 
provided an unprecedented opportunity to advance our knowledge of many monogenic 
disorders(Abdelfatah, McComiskey, et al., 2013; Abdelfatah, Merner, et al., 2013; Ahmed et 
al., 2004; Doucette et al., 2009; Merner et al., 2008; Moore et al., 2005; Young et al., 2001). 
Compared to more ethnically diverse populations that possess a more heterogenous gene pool, 
homogenous founder populations present many advantages in gene discovery research 
endeavours, including both Mendelian and complex disorders. Relative to other founder 
populations, NL is comparatively young (<20 generations), providing an ideal research 
environment to identify the genetic basis that underlies many diseases(Rahman et al., 2003).  
 According to archeological records, NL has been populated longer than any other 
location in North America. Approximately 18,000 years ago during the Last Glacial Maximum, 
the remnants of the Laurentide ice sheet disappeared, giving rise to vast landmasses positioned 
at the Northeastern shelf of Canada. While the landmass of Island portion of Newfoundland is 
approximately 100,000 km2, Labrador is almost three times its size that covers and estimated 
295,000 km2. The availability of inhabitable land provided an ideal location for the first 
indigenous people, including the Maritime Archaic, Palaeoeskimo, and Beothuk, to establish 
Labrador and the island of Newfoundland roughly 10,000 and 6,000 years ago, respectively. 
Recent mtDNA studies suggest that the relationships between these culturally distinct peoples 
predates their arrival by land across the continent of North America(Duggan et al., 2017). 
 In the turn of the 16th century, the arrival of John Cabot to Cape Bonavista marked the 
discovery of NL by European explorers. The earliest European colonies date back to the early 
1600’s, which were founded by English and Irish fisherfolk that came to the island to exploit 
the summer cod fishery. The fishing industry continued to grow, drawing in settlers that 
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immigrated to the island, reaching a population of roughly 12,000 people in 1775 (Figure 
1.14a). By the late 19th century, the fisheries became so lucrative that hundreds of outport 
fishing communities were established along a rugged 10,000 kilometer of coastline (Figure 
1.14b). Although an estimated 200,000 individuals resided in NL by 1890, more than 95% of 
residents were native born and the descendants of approximately 20,000 English (Protestant) 
and Irish (Roman Catholic) fisherfolk(Mannion & Memorial University of Newfoundland. 
Institute of Social and Economic Research., 1977). Geographic and religious segregation led to 
the establishment of this genetic isolate that exhibits high inbreeding coefficients and genetic 
homogeneity(Bear et al., 1987, 1988). Today, NL has stratified into 3 distinct population 
clusters of Protestant, Roman Catholic and North American Indigenous peoples, the latter being 
relatively small (Zhai et al., 2016). These properties make the NL population an extraordinary 
resource for studying monogenic disorders. An excellent example of this is arrhythmogenic 
right ventricular dysplasia type 5 (ARVD5; MIM: 604400), an autosomal dominant condition 
that is characterized by the fibro-fatty replacement of the heart ventricles, leading to sudden 
death in young people. This lethal condition is caused by a heterozygous missense variant in 
TMEM43 (p.Ser358Leu; Merner et al., 2008), which was identified in >25 NL families. This 
pathogenic allele was found to be imported from Europe and dates back to early medieval ages 
(400 – 700 AD), predating today’s European nations(Milting et al., 2015). Compared to a 
global incidence of 1 in 5,000, ARVD5 is enriched in the NL population (1 in 800 – 1,000) due 
to founder effects of the TMEM43 (p.Ser358Leu) allele(Kathy Hodgkinson, Personal 
communication: Discussion on the ARVD5 epidemiology in Newfoundland -October 2018).  





















Figure 1.14. Colonization of the Newfoundland genetic isolate. a) The island population was 
initially colonized by English (Protestant) and Irish (Roman Catholic) fisherfolk which reached 
a population of ~12,000 in the Bonavista/Trinity/Coneception Bay area, b) The natural 
expansion of the initial colony led to the development of hundreds of outport fishing 
communities by the late 19th century. This image is licensed under Creative Commons 
Attribution 4.0 International License, adapted from (Contributors9) 
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through the establishment of a larger population, which has descended from a small number of 
colonizing ancestors(Tom Strachan, 2010). Founder populations possess many advantages in 
the mapping and identification of disease genes. Given the limited number of early settlers, 
disease alleles are often enriched in founder populations, which emerge from a common 
ancestor(Kristiansson et al., 2008). Many well-known examples of founder effects include the 
Canadian Mennonites, French (Northeastern Québec), Hutterites, Icelandic, Dutch and the 
Finnish populations, which possess recurrent disease alleles that cause Fanconi anemia(de Vries 
et al., 2012), myotonic dystrophy(Yotova et al., 2005), limb girdle muscular dystrophy(Boycott 
et al., 2008), early onset atrial fibrillation(Ebenesersdottir et al., 2018), hearing loss(Fransen et 
al., 2001), and Usher syndrome type 3a(Pakarinen et al., 1995) respectively. In comparison to 
genetically diverse urban areas that rely on nuclear families to perform genetic studies, founder 
populations, such as NL, are typically characterized by a higher frequency of large families 
with deep genealogies. In addition, these families often descend from a common ancestor, 
forming a larger clan(Lupski et al., 2011). This advantage permits cascade sequencing on 
candidate variants in many affected family members who share much more of the genome, 
compared to a single person in a nuclear family. Although this approach allows geneticists to 
more readily identify causative pathogenic variants, there are challenges related to using NL 
families in gene identification studies. Many large family members reside in remote areas that 
are isolated from tertiary hospitals, making clinical ascertainment more arduous. Without a 
complete family history and phenotype description, members could erroneously be labeled 
unaffected when they are in fact affected. Additionally, detecting phenocopies within larger 
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families is difficult with limited clinical data, which adds another level of complexity when 
interpreting co-segregation results from cascade sequencing. 
 The NL population has proven to be an exceptional resource for the study of the genetic 
basis of hereditary hearing loss. The inaugural Director of the Provincial Medical Genetics 
Program at Eastern Health, Dr. Elizabeth Ives, was consulted by the Department of Education 
(Dr. Claire Neville-Smith) to look at the increased incidence of deafness along the South shore 
of province. Subsequently, the genetic basis of this hearing loss for the first NL family was 
discovered in 2001(Young et al., 2001). To do this, Young et al(Young et al., 2001) performed 
genome-wide SNP genotyping and linkage analysis on a 6-generation family (Family C) 
recruited by Dr. Claire Neville-Smith and Dr. Ives. A logarithm of the odds (LOD) score of 
11.58 was achieved at 4p16, which overlapped with, DFNA6, DFNA14 and DFNA38 (MIM: 
600965). Full sequencing of Wolframin (WFS1; MIM: 606201) revealed 5 benign 
polymorphisms and 6 novel heterozygous variants. Importantly, pathogenic biallelic variants in 
WFS1 also cause Wolfram syndrome (MIM: 222300), a rare and severe autosomal recessive 
neurodegenerative condition that is characterized by diabetes mellitus, optic atrophy, and 
hearing loss. Extensive genotyping in the extended pedigree and haplotype analysis identified a 
disease haplotype co-segregating with isolated hearing loss across multiple generations in 
Family C, demonstrating that WFS1 c.2146G>A (p.Ala716Thr) was causing DFNA38. Cascade 
sequencing revealed that all affected WFS1 c.2146G>A heterozygotes display nonsyndromic 
low-frequency hearing loss. Crucially, one Family C homozygote was identified who developed 
juvenile diabetes mellitus and a hearing profile that was not consistent with WFS1 c.2146G>A 
heterozygotes, This finding was a seminal aspect of the WFS1 discovery, indicating that some 
homozygous mutant alleles may manifest as a mild or intermediate Wolfram syndrome 
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phenotype. In addition, this discovery demonstrated that variants in a gene known to cause a 
recessive, syndromic form of hearing loss can also cause a dominant disorder, in this case 
isolated hearing loss (Young et al., 2001). 
Since the inaugural WFS1 study, additional pathogenic hearing loss variants have been 
identified in the NL population(Abdelfatah, McComiskey, et al., 2013; Abdelfatah, Merner, et 
al., 2013; Ahmed et al., 2004; Doucette et al., 2009; McComiskey, 2010; Squires, 2015), which 
has led to the development of a screening protocol that aimed to ascertain families who were 
positive for previously described deafness alleles. This effort included the screening of all 
family probands for WFS1 c.2146G>A(Young et al., 2001), TMPRSS3 (MIM: 605511) 
c.207delC(Ahmed et al., 2004) and c.782+3delGAG, PCDH15 (MIM: 605514) 
c.1583T>A(Doucette et al., 2009), and SMPX (MIM: 300226) c.99delC(Abdelfatah, Merner, et 
al., 2013), two large deletions in GJB6 (MIM: 604418, delD1351830 and delD1351854) and 
the most common hearing loss variant, GJB2 (MIM: 121011) c.35delG. Subsequently, families 
whose deafness could not be explained by known variants were prioritized for downstream 
genomic analyses, based the configuration of their audiogram and were categorically grouped 
as having low, mid or high frequency hearing loss audioprofiles. In order to identify candidate 
hearing loss genes, phenotypic data were submitted to Audiogene(Hildebrand et al., 2009), a 
web-based software program that compares audioprofiles to known average audiograms of 34 
deafness loci. Consequently, sequence variants in candidate genes were submitted to in silico 
programs (SIFT, Polyphen-2 and Mutation Taster) and tested for co-segregation within hearing 
loss families. Local MAF’s were determined by screening each candidate variant in ethnically-
matched population controls. Through these efforts, the Young laboratory identified MT-RNR1 
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m.1555A>G(Squires, 2015), COCH c.151 C>T(McComiskey, 2010), and  KCNQ4 
c.806_808delCCT(Abdelfatah, McComiskey, et al., 2013) throughout the NL population.  
The NL Hereditary Hearing Loss Project has enrolled over 200 families into the study 
who have been screened for 23 pathogenic variants (Appendix C), which has led to establishing 
the Centre for Genomics-Based Research and Development in Hearing Science in Grand-Falls 
Windsor, NL. This facility is equipped with a comprehensive suite of clinical audiology tools 
designed to accelerate our understanding of genotype-phenotype correlations. Upon reviewing 
retrospective medical histories, extensive hearing loss clinical ascertainment, as well as in-
depth study participant interviews, several family pedigrees were extended with well-described 
phenotype data. Several of these families were negative for known NL hearing loss variants; 
therefore, these kindreds were promising candidates for downstream genome-wide SNP 
genotyping and linkage analysis. Even though linkage analysis is a traditional “classical 
genetics” tool that is routinely used in forward genetics, it is quite powerful when used in 
combination with more modern next-generation sequencing (NGS) technologies, such as whole 
exome (WES) or whole genome (WGS) sequencing. Even though WES alone has the ability to 
identify several predicted pathogenic variants in known deafness-associated genes(Lewis et al., 
2018), the genetic etiology of hearing loss in many families remains unknown. Moreover, 
Lewis et al (2018) highlighted a significant pitfall of using WES in the clinical setting, noting 
that segregation analysis of candidate variants within larger families is an asset to hearing loss 
gene discovery and diagnosis. In addition to discerning pathogenic hearing loss variants, larger 
multiplex families permit linkage analysis, which allows geneticists to reduce a list of tens of 
thousands of variants to a smaller subset of more promising candidates. Given that linkage 
analysis is based on well-established statistical models, this approach provides sufficient 
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evidence to disregard variants residing outside of identified critical regions(Ott et al., 2015). In 
light of the millions of variants across the human genome(Sherry et al., 2001), combing NGS 
with linkage analysis in the post-genome area expedites the discovery of disease genes, 
especially with autosomal dominant conditions(Ott et al., 2015).  
 Some of the earliest molecular characterization of hearing loss and its syndromes 
heavily relied on whole-genome linkage analysis within clinically well-described families, 
which maps informative genetic markers to defined critical chromosomal intervals that 
encompass a disease-causing variants(Botstein & Risch, 2003). However, due to a limited 
number of meiosis, critical regions were broad, spanning several megabases that included 
hundreds of genes. These genes were prioritized for a variety of downstream positional cloning 
strategies, including artificial chromosome (BAC)-mediated cloning(Mburu et al., 2003; A. 
Wang et al., 1998), the sequencing of genes based on their functional relatedness or expression 
in the auditory system(X. Liu et al., 2010), or candidate gene selection guided by hearing loss 
mouse models(Kurima et al., 2002; Naz et al., 2004). Using a linkage analysis approach, the 
first hearing loss locus was mapped to chromosome Xq in 1988(Wallis et al., 1988), which led 
to the identifying POU3F4 (MIM: 300039) as the first deafness gene several years later(de Kok 
et al., 1995). Subsequently, Leon et al (1992) revealed the first autosomal deafness locus, 
DFNA1, where DIAPH1 was found to be the causative hearing loss gene shortly 
thereafter(Lynch et al., 1997). In the 1997, Kelsell et al (1997) first described GJB2 as the 
DFNB1 and DFNA3 gene, a monumental discovery that led to great interest in hearing loss 
genetics. Within that same year, the most common GJB2 variant (c.35delG) was 
reported(Carrasquillo et al., 1997). Importantly, the GJB2 c.35delG variant was identified with 
Belgian, the UK, and the American population, and was revealed that this variant resided on an 
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ancient founder haplotpye that arose in European many centuries ago(Van Laer et al., 2001). 
These findings led to an international, multicenter collaboration that screened GJB2 in ~1,500 
affected subjects(Snoeckx et al., 2005). This study found that GJB2 c.35delG accounted for 
65% of mutant alleles; although, 90% of participants were of European descent, with a carrier 
rate of 2-4%(Snoeckx et al., 2005). Given that the mapping of these early loci and genes largely 
predated the human genome project, this painstaking process was of great value to the global 
hearing loss genetics field. Due to the limitations of molecular genetics tools of the time, many 
physical genetic maps contained significant errors that sometimes produced incorrect linkage 
mapping(Snoeckx et al., 2004). 
Other early pioneering hearing loss gene discoveries heavily relied on reverse genetic 
approaches using the mouse (Mus musculus) model organism. The identification of MYO7A 
(MIM: 276903) as the USH type 1B (MIM: 276900) gene exemplifies the important role of 
reverse genetics in human hereditary hearing loss. By investigating the shaker-1 mouse model 
that was characterized by circling and head-tossing due to vestibular dysfunction, as well as 
progressive hearing loss, Weil et al (1995) identified a YAC subclone that hybridized to a 2-kb 
region on chromosome 7. This subclone was comprised of several Myo7a exons, which was 
homologous to the human USH1B locus at 11q13.5, prompting the sequencing of the MYO7A 
gene in several affected families. These sequencing efforts revealed five different pathogenic 
MYO7A variants in five unrelated families, identifying the genetic basis of USH type 1B. This 
discovery provided significant evidence of the role of MYO7A in hereditary hearing loss, which 
established its role in non-syndromic DFNB2 (MIM:600060; Guilford et al., 1994). In a similar 
approach, Avraham et al (1995), investigated the Snell's waltzer deafness mouse model. This 
mouse model harbored a radiation-induced inversion of chromosome 9 that was 2 cM in size. 
 40 
Sequencing of inversion breaks identified a transcribed region that shared 89% sequence 
homology with porcine Myo6. Like the shaker-1, the Snell's waltzer model also displayed 
features, which were consistent with hearing loss and vestibular dysfunction. These data 
generated much interest in human MYO6 (MIM: 600970), which lead to solving the DFNB37 
(MIM: 607821) and DFNA22 (MIM: 606346) hearing loss loci. 
 
1.2.4 Next-Generation Sequencing Technologies 
In the early 2010s, many high throughput NGS technologies were commercially 
available; namely, Pacific Bioscience, Roche 454, Ion Torrent and Illumina(Loman et al., 
2012). However, the Ion Torrent and Illumina platforms are predominantly used today ( 
reviewed in Levy & Myers, 2016). Ion Torrent NGS offers both targeted and WES platforms. 
Importantly, Ion Torrent library capture is PCR-based by multiplexing hundreds of thousands 
of primers that are designed against according to the desired target regions. Once amplified, 
targeted or whole exome libraries are then ligated on to an individual ion sphere particle, which 
are then loaded onto a semiconductor chip. Millions of wells are present within the 
semiconductor chip, each of which contains an individual ion sphere particle, and a PCR 
template stand for downstream sequencing. During the sequencing process, each of the four 
nucleotides are flowed into each well that allows for the synthesis of a complementary strand of 
DNA. Crucially, as each nucleotide is incorporated, protons (H+) are released from the growing 
complementary DNA strand. In turn, this process changes the pH within the well, which is 
measured and recorded as a specific base pair that was incorporated in the complementary 
DNA template stand. In contrast, Illumina offers targeted, WES and WGS solutions for gene 
discovery, and exploits a different approach to sequencing. Firstly, DNA sample preparation is 
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drastically different, relative to Ion Torrent. This process involves the fragmentation of 
genomic DNA through sonication or enzymatic digestion. Subsequently, universal adaptor 
sequences are ligated to the ends of the fragmented DNA molecules, followed by clustering on 
a glass flow cell slide. Each of the flow cell lanes are coated with lawns of oligonucleotides that 
are complementary to the universal adaptor sequences. Clustering involves the hybridization of 
the DNA library to the oligonucleotide lawns, which are then amplified by a polymerase into 
clonal “clusters”. After clustering, sequencing begins with the extension of the universal primer 
to produce the first read. With each cycle, fluorescently labeled nucleotides compete for 
addition to the growing sequence. Only one is incorporated based on the sequence of the 
template strand. After nucleotide incorporation, the cluster are excited by a light source and 
specific fluorescent signal is emitted, corresponding to a specific nucleotide – a method referred 
to as “Sequencing-by-synthesis”.  
While WES and targeted sequencing strategies have drastically improved the molecular 
diagnosis of disease in the clinical setting, many cases go unresolved. From a genomics lens, 
this problem arises due to a significant limitation and biases in WES and targeted sequence 
capture planforms. For example,  The Ion Torrent AmpliSeq RDY Exome (Thermo-Fisher-
Scientific, 2019) and the Illumina TruSeq DNA Exome (Illumina, 2019) kits are designed to 
capture +96% of genes contained within the Consensus CDS (CCDS) project(Damiati et al., 
2016; Du et al., 2016; O'Leary et al., 2016; Q. Wang et al., 2017). Even though this is a 
significant improvement over traditional Sanger sequencing methods, approximately +3% of 
genes within the CCDS project, and the over 8 million expressed sequence tags (ESTs) are not 
sequenced using this approach. However, one approach to overcoming these challenges is to 
perform WGS, which covers >98% of the entire genome with no biases towards specific 
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databases, and is more sensitive in detecting pathogenic variants in gene discovery projects 
(Belkadi et al., 2015). 
 
1.3 Summary and Study Goals 
Hearing loss is one of the most common hereditary conditions, affecting millions of 
people around the world. Despite the identification of over 143 hearing loss genes, many loci 
remain unsolved. Although an estimated 1/3 of genes within autosomal dominant loci have 
evaded discovery(Van Camp G, 2015), the availability of large extended families with well-
described phenotypes can reduce the burden of broad critical regions and a diverse human 
genome. In addition to relying on several genomic technologies, such as NGS and linkage 
analysis, incorporating functional RNA analyses will aid in deciphering the complexity of the 
transcriptome. This research project is a culmination of two decades of work to solve the 
genetic basis of several types of hearing loss. Throughout this thesis, we aim to identify and 
discover the genetic basis of autosomal dominant and recessive sensorineural hearing loss, and 
its syndromes, by exploiting a comprehensive multi-omic approach, discerning the functional 
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Genetic isolates provide unprecedented opportunities to identify pathogenic variants and 
explore the full natural history of clinically heterogeneous phenotypes such as hearing loss. Our 
clinical audiologist noticed a unique audioprofile, characterized by prelingual and rapid 
deterioration of hearing thresholds at frequencies >0.5 kHz in several adults from unrelated 
families from the island population of Newfoundland. Previously performed targeted serial 
Sanger sequencing of probands for known deafness alleles in this founder population (n = 23) 
was negative. Whole exome sequencing in four members of the largest family (R2010) 
identified a CLDN14 (DFNB29) variant [c.488C>T; p.(Ala163Val)] that causes autosomal 
recessive sensorineural hearing loss. Although not associated with deafness or disease, 
CLDN14 p.(Ala163Val) has been previously reported as a variant of uncertain significance 
(VUS). Targeted sequencing of 169 deafness probands identified one homozygote and one 
heterozygous carrier. Genealogical studies, cascade sequencing and haplotype analysis across 
four unrelated families showed that all subjects with the unique audioprofile (n = 12) were also 
homozygous for p.(Ala163Val) and shared a 1.4 Mb DFNB29-associated haplotype on 
chromosome 21. Most significantly, sequencing 175 NL population controls revealed 1% of the 
population is heterozygous for CLDN14 p.(Ala163Val), consistent with a major founder effect 
in Newfoundland. The youngest CLDN14 [c.488C>T; p.(Ala163Val)] homozygote passed 
newborn screening and had normal hearing thresholds up to 3 years of age, which then 
deteriorated to a precipitous loss >1 kHz during the first decade. Our study suggests that genetic 





Hearing loss is one of the most common and genetic of all human phenotypes. 
Permanent bilateral sensorineural hearing loss affects 1/500 newborns, and almost twice as 
many adolescents(Morton & Nance, 2006; Richard JH Smith, 1999 ). Although approximately 
two-thirds of prelingual severe hearing loss cases are recessive, only a minority of hearing loss 
cases with a presumed recessive inheritance pattern can be conclusively diagnosed with a clear 
genetic etiology(Sloan-Heggen et al., 2016). Therefore, many recessive cases may be due to 
genetic defects in genes yet to be identified. However, recent studies using new high-
throughput technologies and broader application in multi-ethnic populations report GJB2 yields 
of less than 25%, suggesting a larger role for other recessive genes in prelingual severe 
cases(Sloan-Heggen et al., 2016; Yan et al., 2016). 
Sensorineural hearing loss is characterized by both degree (mild, moderate, severe or 
profound) and configuration (low, mid and/or high frequency) using the standard behavioral 
audiogram. Although clinically heterogeneous, rare pathognomonic audiograms may present 
with surprising regularity in clinics within genetically isolated populations and where patients 
often share a common ancestor due to founder effects. For example, the Finnish and Pakistani 
populations have been invaluable for discovery of deafness genes as population bottlenecks 
(genetic drift) and/or inbreeding increase the likelihood of inheriting recessive alleles that are 
identical by descent(Ahmed et al., 2004; Z. E. Bashir et al., 2013; Lee et al., 2012; Nayak et 
al., 2015). These populations are often characterized by large sibships, deep genealogies and 
higher consanguineous rates. The NL population was founded by ~20,000 Protestant English 
and Roman Catholic Irish settlers. Religious and geographic isolation within small coastal 
fishing (outport) communities(Manion, 1977) has resulted in a higher inbreeding coefficient in 
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the NL population(Bear et al., 1987; Zhai et al., 2015). We have previously identified several 
founder deafness alleles in the NL populations(Abdelfatah, McComiskey, et al., 2013; 
Abdelfatah, Merner, et al., 2013; Ahmed et al., 2004; Doucette et al., 2009; Young et al., 
2001).  
A unique clinical audioprofile of steeply sloping sensorineural hearing loss was noted in 
several unrelated families. Herein, we report a founder missense variant in CLDN14 causing 
precipitous prelingual sensorineural hearing loss in children born with normal hearing 
thresholds. The essential role of CLDN14, a component of tight junctions, was first discovered 
through studies in consanguineous families from the genetically isolated population of 
Pakistan(Wilcox et al., 2001). Tight junctions have been shown to play a significant role in 
maintaining the structural integrity of cells within the inner ear. Other genes encoding tight 
junction proteins, such as MARVEL Domain Containing 2 (MARVELD2; DFNB49; Nayak et 
al., 2015; Riazuddin et al., 2006), have also been implicated in recessive hearing loss. Claudin-
14 is essential for the formation of tight junctions and is expressed in both hair cells and 
supporting cells of the organ of Corti; however, CLDN14 exhibits preferential gene expression 
in sensory hair cells over supporting cells(Ben-Yosef et al., 2003; Scheffer et al., 2015; Wilcox 
et al., 2001). Initially, CLDN14 was considered the cause of congenital recessive and profound 
deafness(Wilcox et al., 2001) and more recently of milder forms of hearing loss(Z. E. Bashir et 
al., 2013). The CLDN14 c.488C>T p.(Ala163Val) allele has previously been reported in 
multiple studies as a variant of uncertain significance (VUS; Purcell et al., 2014; Thorleifsson 
et al., 2009; Toka et al., 2013) and recently identified by Sloan-Heggen et al (2016) as one of 
two VUS in a patient with congenital hearing loss. Our study shows children inheriting two 
copies of the CLDN14 c.488C>T p.(Ala163Val) allele are born with normal hearing thresholds 
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and experience a rapid and progressive loss by 3–4 years of age. Extensive clinical recruitment 
and targeted screening suggest that CLDN14 p.(Ala163Val) represents a major founder variant 
in the Newfoundland population. 
 
2.5 Materials and Methods 
This project is part of a large study of hereditary hearing loss in the Canadian province 
of NL. Informed consent, family history and permission to access medical records and 
audiograms were obtained from all participants by clinicians, as per approved institutional 
review board protocol #01.186 (Human Research Ethics Board, St. John’s, NL, Canada). 
Sensorineural hearing loss was determined by our clinical team when hearing thresholds were 
abnormal, as defined by air and bone conduction results within 10 decibels (dB) of each other 
(i.e., air–bone gaps of 10 dB or less). In addition, the team obtained both retrospective and 
prospective audiograms and health records for all study participants. 
In the course of ongoing clinical recruitment, a rare but consistent clinical audioprofile 
characterized as steeply sloping, sensorineural hearing loss above 0.5 kHz with mid- and high-
frequency thresholds in the severe to profound range (Figure 2.1a – d) was noted by our clinical 
audiologist, Anne Griffin. When this project first began, we were unaware of common ancestry 
between Families R2033, R2075 and R2010 (Figure 2.2). In fact, during our outreach field trip 
to Burin Peninsula, we were only focused on the clinical ascertainment of Family R2010, as 
well as collecting DNA samples. When examining the pedigree structure and inheritance 
pattern of hearing loss in Family R2010, we were of the opinion that this was an autosomal 
dominant form of hearing loss. The reason we believed this is because PID IV-4 has hearing 
loss, which is vertically transmitted to all his descendants (Figure 2.2). Moreover, we  
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Figure 2.1. Rare, precipitous audiologic phenotype caused by CLDN14 (c.488C>T; 
p.Ala163Val) in an Irish clan. a) Pure tone audiogram of Family R2010 proband (PID V-9) and 
sister (PID V-10), b) Pure tone audiogram series for PID VI-2 (Family R2075) showing normal 
hearing at age 2 years and a progressive hearing loss apparent by 4 years of age, c) first and d) 
second decade pure tone audiogram of affected subjects. Yellow shaded area indicates range of 
normal hearing. Hearing thresholds are measured in decibels hearing level (dB HL), X = left ear 
(air conduction), O = right ear (air conduction), > = left ear (bone conduction), î = no response 

















Figure 2.2. Combined pedigrees of 3 families (R2033, R2075 and R2010) with rare, precipitous 
audiologic phenotype that connect to a common ancestor. Shaded symbols: precipitous 
sensorineural hearing loss. Half shaded symbols: unspecified hearing loss.  
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noted that a distant relative, PID VI-4, also inherited hearing loss from his mother, PID V-9, 
while his father, PID V-8, exhibited normal hearing thresholds across all frequencies (Figure 
2.1 and Figure 2.2). In light of this strong family history, we considered that PID VI-4’s 
deceased grandmother, PID IV-6, may have been clinically affected, which would support an 
autosomal dominant hearing loss inheritance pattern.  Upon further inspection of other hearing 
loss families in our ongoing hearing loss study, our clinical audiologist noticed that this rare 
precipitous hearing loss phenotype was present in 2 additional families, R2033 and R2075 
(Figure 2.1). Despite an apparent dominant inheritance pattern in family R2010, this precipitous 
hearing loss appeared to be recessive in families R2033 and R2075, which was rather puzzling 
during the early stages of this project. This prompted us to take a closer look at these families 
and consider the idea of shared ancestry between these three families. On the premise that 
subjects with this hearing loss pattern also shared a recent common ancestor, Anne Griffin and 
Sarah Predham (project genetic counsellor) used the distinct audioprofile to guide clinical 
recruitment. 
 
2.5.1 DNA Preparation, Targeted Sequencing and Audioprofiling 
Prior to this study, genomic DNA was extracted from peripheral blood using a simple 
salting out protocol(Miller et al., 1988). All recruited probands were then screened for 
population-specific deafness alleles (Appendix C; Abdelfatah, McComiskey, et al., 2013; 
Abdelfatah, Merner, et al., 2013; Ahmed et al., 2004; Doucette et al., 2009; Young et al., 
2001). To identify other candidate genes to screen, audiograms were submitted to 
Audiogene(Hildebrand et al., 2009) for computerized comparison with known average 
audiograms of 16 autosomal dominant loci, under the assumption that hearing loss was 
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segregating as an autosomal dominant trait in these NL families. Bidirectional Sanger 
sequencing (ABI PRISM 3500XL DNA Analyzer; Applied Biosystems, Foster City, CA, USA) 
with standard PCR assay using Primer3(Untergasser et al., 2012) was used to screen candidate 
variants and genes(Merner et al., 2008). DNA sequences were visualized using Mutation 
Surveyor Software (version 4.07, SoftGenetics LLC State College, PA 16803). 
 
2.5.2 Whole-Exome Sequencing and Variant Filtration 
Whole exome libraries were prepared for four members of Family R2010 using the Ion 
Torrent AmpliSeq RDY Exome Kit (Life Technologies, Cat. #A27193; Figure 2.2). Exome 
library purification, adapter ligation and barcoding were done using the Ion PI Hi-Q OT2 200 
kit (Life Technologies, Cat. #A26434). Library purification was performed and quantified with 
the Ion Library Quantification Kit (Life Technologies, Cat. #4468802) and then loaded onto a 
PI v3 chip and sequenced with the Ion Torrent Proton Sequencer. Single-nucleotide variants 
(SNVs) and insertion/deletions (INDELs) were called (GATK, v3.5) and annotated by 
bioinformaticians using SnpEff (v4.1; http://snpeff.source- forge.net/), and SNVs were filtered 
against publically available SNP databases (ExAC Browser, http://exac.broadinstitute.org/; 
dbSNP, http://www.ncbi.nlm.nih.gov/projects/SNP/; 1000 genomes, http://www.1000geno- 
mes.org; ClinVar, https://www.ncbi.nlm.nih.gov/clinvar/). We assessed the impact of SNVs at 
the protein level with SIFT, PolyPhen-2, and MutationTaster. Filtered SNVs had a minimum of 
20× coverage, a predicted moderate/high impact (nonsense, frameshift, missense, splice sites) 
and a minor allele frequency (MAF) of <1%. Two different variant filtration analyses were 
performed. In our first analysis, we filtered for all heterozygous variants that were present in 
affected (PID V-9, V-17 and VI-4) and absent in unaffected (PID V-9) family members (Figure 
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2.2), given that we initially thought that this was a dominant family. Since this rare precipitous 
hearing loss followed a recessive inheritance pattern in Families R2033 and R2075 (Figure 2.2), 
we filtered for all variants that were homozygous in affected (PID V-9, V-17 and VI-4) and 
heterozygous in unaffected (PID V-9) family members in our second analysis. The rationale 
behind conducting a recessive analysis was due the geographic location of these families on the 
Burin Peninsula. Carrier frequencies could be higher in this region due to founder effects 
resulting from consanguineous relationships, as well as religious and geographic barriers. This 
founder effect could certainly increase the likelihood of producing homozygous offspring. Even 
though pseudodominance was the more likely scenario, there wasn’t enough evidence to 
exclude a dominant inheritance pattern. The apparent vertical transmission of hearing loss in 
the pedigree (Figure 2.2) could be due to either a dominant gene with reduced penetrance, or a 
recessive gene with a pseudodominant inheritance pattern, therefore we conducted both 
autosomal dominant and recessive analyses. 
 
2.5.3 Cascade Sequencing and Haplotype Analysis 
Potential pathogenic variants were subjected to cascade screening in all available 
relatives across three families observed to have the same rare audioprofile (Families R2010, 
R2033 and R2075), as well as 175 ethnically-matched controls. Microsatellites flanking 
candidate genes were genotyped according to standard procedures(Abdelfatah, McComiskey, et 
al., 2013; Abdelfatah, Merner, et al., 2013) and alleles were called using GeneMapper software 
v4.0. Haplotypes were reconstructed manually and compared across families. In addition, 




2.6.1 Clinical Evaluation 
Our clinical audiologist (AG) noted that probands (from Families R2010, R2075 and 
R2033) all shared a unique hearing loss pattern. The proband of Family R2010 (V-9; Figure 
2.2) presented at 36 years of age with the characteristic pattern of normal low-frequency 
thresholds, steeply sloping to severe bilateral, symmetrical, sensorineural hearing loss 
throughout mid- and high-frequencies (Figure 2.1a). Age-appropriate audiologic tests of the 
proband’s son (VI-4; Figure 2.2) at 1 month and 1 year of age were normal. Serial audiograms 
on PID VI-2 (Figure 2.1b; Family R2075) show normal hearing thresholds across frequencies 
up to 3 years of age, with subsequent rapid progression of hearing loss affecting high-
frequencies first. Significant hearing loss of variable severity is already present in children aged 
5–7 years (Figure 2.1c), which include probands of families R2033 and R2075. By the middle 
of the second decade of life, these children uniformly exhibit the distinctive steeply sloping 
audiogram (Figure 2.1d). The hearing loss progresses slowly during subsequent decades, 
primarily in the mid–high frequencies, with relatively well-preserved low-frequency thresholds. 
For adults, some variation in thresholds at 0.5 kHz is observed (PID V-10; Figure 2.1a) but 
otherwise the adult presentation is relatively uniform. 
 
2.6.2 Targeted Sequencing and Audioprofiling 
Prior to our study, targeted sequencing was carried out on probands for known deafness 
alleles (previously identified in this population; Appendix C) but none were found. Several 
gene candidates, as suggested by Audiogene(Hildebrand et al., 2009), were also Sanger 
sequenced, including COCH, KCNQ4 and TMC1. A rare variant in TMC1 (c.421C>T; MAF of 
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0.01%) was identified and predicted to cause an arginine to tryptophan substitution at position 
141 of the protein amino acid sequence. The variant was predicted to be deleterious by SIFT 
and probably damaging by PolyPhen-2 and Panther. Although identified in both the proband 
(PID V-9) of Family R2010 and her son (PID VI-4), the c.421C>T variant did not co-segregate 
with mid–high-frequency loss (Figure 2.3). 
 
2.6.3 Whole-Exome Sequencing  
Whole exome sequencing on Family R2010 using three affecteds (V-9, VI-4 and V-17) 
and one unaffected parent (V-8) (Figure 2.2) yielded >35,000 total variants. Under a dominant 
model, 34 heterozygous variants were filtered by our bioinformaticians (Table 2.1). However, 
none of these variants resided within known deafness genes/loci (http://hereditaryhearing-
loss.org/). Under a recessive model, they filtered four homozygous variants (Table 2.2) One of 
these, CLDN14 (DFNB29) is a known deafness gene expressed in the sensory epithelium of the 
organ of Corti of the inner ear(Scheffer et al., 2015; Wilcox et al., 2001). CLDN14 consists of 
three exons and two isoforms, and encodes a protein containing four transmembrane domains. 
The CLDN14 p.(Ala163Val) point variant (Figure 2.4) identified in Family R2010 predicts 
substitution of an alanine to a valine at the beginning of the fourth transmembrane domain 
(Figure 2.5) and is highly conserved (Figure 2.6). The CLDN14 c.488C>T allele was first 
identified in the Icelandic population(Thorleifsson et al., 2009). Globally, 
the CLDN14 c.488C>T variant has an MAF of 0.02564% (ExAC Browser, http:// 
exac.broadinstitute.org/) and has been reported in both European and African populations. The 
heterozygous CLDN14 allele (human GRCh37/hg19: g. 37833506 G>A, NM_012130.3: c.488 








Figure 2.3. TMC1 c.421C>T Segregation Analysis in Family R2010. This is a Sub-pedigree of 
the CLDN14 Newfoundland illustrating that TMC1 c.421C>T does not segregate with hearing 
loss. Shaded symbols: precipitous sensorineural hearing loss. Half shaded symbols: unspecified 




Table 2.1. Thirty-one Heterozygous variants identified in PID V-9, VI-4 and V-17 (Family 
R2010; Figure 2). None of these variants resided within known deafness genes/loci or were 





Table 2.2. Four Homozygous variants identified in PID V-9, VI-4 and V-17 (Family R2010; 
Figure 2). No reports exist of CUL7, PRKDC and ZNF404 being involved in hearing loss. 
Additionally, these three genes did not reside within known deafness genes/loci. CLDN14 is a 
known hearing loss gene that causes DFNB29, which perfectly segregated within a 






















Figure 2.4. Sequence electropherogram of CLDN14 (c.488C>T; p.Ala163Val). Red box 














































Figure 2.5. Location of pathogenic variants in Claudin-14. Colored amino acid residues indicate 
previously reported claudin-14 alleles. Arrow indicates position of CLDN14 c.488C>T 
(p.Ala163Val). Adapted from: Bashir, Z.E., Latief, N., Belyantseva, I.A., Iqbal, F., Riazuddin, 
S.A., Khan, S.N. et al. Phenotypic variability of CLDN14 variants causing DFNB29 hearing 
loss in the Pakistani population. J Hum Genet. 58, 102-108 (2013). This article is distributed 
under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and 
reproduction in any medium, provided you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons license, and indicate if changes were made. 





































Figure 2.6. Conservation of the Claudin-14 protein using Clustal Omega and WebLogo display. 
Homo sapiens (NP_001139551.1), Pan paniscus (XP_008975916.1), Mus musculus 
(NP_001159398.1), Rattus norvegicus (NP_001013447.1), Canis lupus familiaris 
(XP_013965166.1), Gallus gallus (XP_015155717.1), Gekko japonicas (XP_015277878.1), 
Pelodiscus sinensis (XP_006126056.1), Xenopus laevis (NP_001086045.1), Danio rerio 





(Variation ID: 228519), and has been submitted to large scale sequencing projects, including 
ExAC browser (MAF: 0.02564%), 1000 genomes (MAF: 0.04%), and the Grand Opportunity 
Exome Sequencing Project (MAF: 0.05%). In addition, this allele has been reported in several 
control samples from other study cohorts within the USA(Toka et al., 2013), Sweden(Purcell et 
al., 2014), and Africa (ExAC browser). The majority of known pathogenic CLDN14 variants 
reside within one of the transmembrane domains in Claudin-14 (Figure 2.5; R. Bashir et al., 
2010; Charif et al., 2013; Lee et al., 2012; Wattenhofer et al., 2005; Wilcox et al., 2001)). 
Functional studies of pathogenic CLDN14 variants have demonstrated the importance of 
transmembrane domains with respect to protein topology and folding, as well as proper spatial 
localization within cells. For example, previous localization experiments have shown that the 
p.Val85Asp and p.Gly101Arg deafness variants within domain II (Figure 2.5) fail to form tight 
junctions due to the mislocalization of claudin-14 protein to the cytoplasm, in 
vitro(Wattenhofer et al., 2005). Since p.(Ala163Val) is predicted to change a highly conserved 
amino acid within the fourth transmembrane domain (Figures 2.4 – 6), we suspect a similar 
impact regarding the spatial localization of claudin-14 to the plasma membrane, leading to the 
cells’ inability to form tight junctions. While previous research demonstrated the importance of 
amino acid conservation within claudin-14 transmembrane domains, experimental functional 
studies are needed to prove CLDN14 c.488C>T, p.(Ala163Val) pathogenicity. The CLDN14 
gene is essential in maintaining auditory function, as it has been identified as a critical 
component of tight junctions (Figure 2.7), which play a critical role in maintaining the 
electrochemical gradient observed in the organ of Corti. Briefly, hair cell stereocilia are bathed 
in potassium-rich endolymph, while the basolateral surface of the hair cell body is surrounded 






























Figure 2.7. Schematic diagram demonstrating the molecular structure of tight junctions. This 




gradient is maintained by the reticular lamina, where CLDN14 plays a key role in forming tight 
junctions (Figure 2.8). 
 
2.6.4 Cascade Sequencing and Haplotype Analysis  
Cascade sequencing in all available subjects from Families R2033 and R2075 showed that 
affecteds with the distinct precipitous mid–high-frequency hearing loss (Figure 2.9, filled 
symbols) were also homozygous for CLDN14 p.(Ala163Val) (Figure 2.4). Subjects with a flat 
loss, such as PID IV-4 and his descendants (V-5, V-7 and VI-4) lacked the recessive CLDN14 
variant (Figure 2.10). This pattern is consistent with our hypothesis that CLDN14 
p.(Ala163Val) is a likely pathogenic, recessive allele where homozygosity results in a distinct 
precipitous mid–high-frequency hearing loss. Relatives inheriting a single copy (carriers) or 
wild type do not have this pattern. As per to the ACMG standards and guidelines(Richards et 
al., 2015), CLDN14 p.(Ala163Val) is classified as Pathogenic variant (PS4, PM1, PM2, PM3. 
PP1, PP2, PP3, PP4). 
 The cause of hearing loss in subjects with flat audioprofiles is not known, but is clearly 
not due to homozygosity for CLDN14 c.488C>T. Future studies will explore the genetic 
etiology of their hearing loss. Furthermore, screening our cohort of 169 deafness probands 
identified an additional homozygous subject (Family R2072) and two heterozygous carriers. In 
Family R2072, the proband’s mother (with the distinct audioprofile) was also found to be 
homozygous for CLDN14 p.(Ala163Val) and her father a carrier (Figure 2.11). Screening 
population controls identified four carriers out of 175 subjects, estimating an MAF of 1.15% in 
the Newfoundland population and suggesting that this likely pathogenic variant is not rare. 



























Figure 2.8. Cross-sectional diagram illustrating the anatomical location of the cochlear canals 
and their respective ionic composition. * denotes CLDN14 expression. This image is licensed 










































Figure 2.9. Combined pedigrees of 3 families (R2033, R2075 and R2010) with rare, precipitous 
audiologic phenotype connect to a founding couple and share an ancestral DFNB29-associated 
haplotype. Shaded symbols: precipitous sensorineural hearing loss. Half shaded symbols: 



























































Figure 2.11. Pedigree of family R2072, identified in screening of the NL deafness cohort, with 
the rare, precipitous audiologic phenotype who also share the CLDN14 (c.488C>T; 





























a 1.4 Mb ancestral haplotype shared across all four families (Figure 2.7). Haplotype analysis  
shows affected individuals in the four families inherit an ancestral DFNB29-associated 
haplotype on chromosome 21q22.1, signifying clan membership, although biological 
connection for Family R2072 was not found (Figure 2.9 and Figure 2.11). Additionally, we 
sequenced all coding sequences of the CLDN14 gene, including the exon/intron boundaries and 
5′ and 3′ UTRs. We identified a common synonymous variant (c.243C>T; rs219799) within the 
clan, which was incorporated into our DFNB29-associated deafness haplotype. 
 
2.6.5 Genealogical Analysis 
Extension of the pedigrees and review of all audiograms by our audiologist identified 16 
subjects with hearing loss; 10/16 subjects showed the distinct precipitous mid–high-frequency 
hearing loss (Figure 2.2). Subjects with hearing impairment not consistent with the distinct 
precipitous mid–high-frequency pattern include PID IV-3 (whom we have not connected to the 
founding couple) and all descendants of PID IV-4 (Figure 2.2). In these cases, the audiogram 
can be characterized as a flat loss across all frequencies; PID IV-4 had a profound flat loss and 
his descendants (V-5, V-7, VI-3) show a mild flat loss (Figure 2.12). Family interviews 
conducted by Anne Griffin and Sarah Predham determined surnames suggestive of Irish 
descent(Seary, 1977) and connected Families R2010, R2033 and R2075 to a single founding 
couple six generations ago. We noted that the inheritance pattern in the combined pedigree 
suggested either autosomal dominant (with reduced penetrance) or autosomal recessive 
(pseudodominant) inheritance (Figure 2.2). In summary, this population-based study using a 
targeted and whole exome sequencing approach identified a common CLDN14 (DFNB29) 





Figure 2.12. Clan members lacking the recessive CLDN14 [c.488C>T; p.(Ala163Val)] variant 
do not present with the characteristic steeply sloping hearing phenotype, exhibiting a different 
age of onset and hearing threshold progression. a) Profound, flat sensorineural hearing loss with 
an unknown etiology at age 63 (PID IV-4), b PID V-5 (age: 53) presents with borderline hearing 
thresholds, c PID V-7 (age: 58) presents with mild hearing loss with a diagnosis of Meniere’s 
disease, d at age 39, PID VI-3 presents with mild hearing loss, and e a heterozygous CLDN14 
[c.488C>T; p.(Ala163Val)] carrier (PID V-4) exhibits mild hearing loss at age 60. Yellow 
shaded area indicates range of normal hearing. Hearing thresholds are measured in decibels 







Newfoundland families.  
 
2.7 Discussion 
We have determined that a known VUS (CLDN14, c.488C>T, p.(Ala163Val)) is likely 
pathogenic, and causes a precipitous, bilateral and rapid deterioration of hearing thresholds at 
frequencies >0.75 kHz in children, progressing gradually in adults. In addition, it has been 
determined that this Likely Pathogenic variant is enriched in the founder population of the 
island of Newfoundland and is present in ~1% of the population. 
The role of CLDN14 in nonsyndromic hearing loss was first described in two large 
consanguineous families from Pakistan with autosomal recessive profound congenital 
deafness(Wilcox et al., 2001). Recessive CLDN14 alleles manifest as nonsyndromic 
sensorineural hearing loss with considerable phenotypic variability and may present as a 
congenital, mild, moderate–severe or profound loss(R. Bashir et al., 2010; Z. E. Bashir et al., 
2013). In this study, homozygous children had normal hearing thresholds up to 3 years of age 
and overall, a remarkably conserved hearing phenotype. Hearing loss onset is post-lingual 
during the first decade, which progresses from a normal gently sloping to moderate, to a normal 
sloping to profound by the second decade. A combination of pedigree extension and genotyping 
linked four families of Irish ancestry to a founding couple six generations back. 
The claudin family of proteins consists of 24 members with tissue-specific expression. 
Claudin-14 plays a critical role in the formation of tight junction barriers that regulate 
paracellular ion transport(Mineta et al., 2011) and is highly expressed in the kidney, liver and 
the inner ear(Ben-Yosef et al., 2003; Wilcox et al., 2001). Moreover, preferential gene 
expression has been observed in the inner ear, as CLDN14 expression is lower in supporting 
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cells, relative to sensory hair cells(Scheffer et al., 2015; Wilcox et al., 2001). Normal hearing 
function and hair cell depolarization are dependent on tight junctions in the reticular lamina. In 
the organ of Corti, hair cell stereocilia are bathed in potassium-rich endolymph, while the 
basolateral surface of the hair cell body is surrounded by an intercellular (or extracellular) fluid 
continuous with the perilymph(Ferrary & Sterkers, 1998; Furuse & Tsukita, 2006). The 
reticular lamina, formed in part by tight junctions between the apical surfaces of hair cells and 
supporting cells of the sensory epithelium(Gulley & Reese, 1976), creates a barrier isolating the 
endolymphatic fluid from other cochlear compartments, which contain perilymph. Maintenance 
of this ionic gradient is essential for mechanotransduction, which depends on the modulation of 
potassium current flowing from the endolymph into the hair cells through the stereocilia, as 
they are displaced by sound-induced vibrations. The major molecular components of tight 
junctions include a broad group of genes of transmembrane occludins, claudins, and junctional 
adhesion molecules(Kitajiri et al., 2004; Riazuddin et al., 2006). In addition to CLDN14, other 
tight junction genes have been shown to cause hearing loss. For example, pathogenic variants in 
MARVELD2 (MIM: 610572; Riazuddin et al., 2006) and ILDR1 (MIM: 609739; Borck et al., 
2011) are known to cause DFNB49 (MIM: 610153) and DFNB42 (MIM: 609646), 
respectively(Van Camp G, 2015). Disruption of this tight junction barrier alters the ionic 
gradient, increasing the potassium concentration around the hair cell body, compromising 
mechanotransduction, which causes hair cell toxicity, due to prolonged sensory cell 
depolarization, and eventual cell death(Ben-Yosef et al., 2003). 
The CLDN14 p.(Ala163Val) variant reported in this study has been identified in 
previous studies, but not in association with disease. It was first reported as a VUS by 
Thorleifsson et al(Thorleifsson et al., 2009) in a large Iceland/Netherlands GWAS cohort study 
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examining SNPs associated with kidney stones and bone mineral density, and more recently by 
Toka et al (2013), who detected the CLDN14 p.(Ala163Val) allele in 3 of 1230 study 
participants for another kidney function study. The heterozygous p.(Ala163Val) allele was also 
found in a Swedish GWAS study examining the polygenic nature of schizophrenia(Purcell et 
al., 2014). The heterozygous p.(Ala163Val) allele was submitted 31 times to ExAC browser, 29 
alleles from European descent and 2 from the African population. In a recent American study 
including 1119 deafness probands, a cohort made up of 62.3% autosomal recessive 
cases(Sloan-Heggen et al., 2016) used a targeted sequencing approach and the most commonly 
implicated genes were GJB2, MYH9, OTOA, PCDH15, SLC26A4, STRC, TMC1, TMPRSS3 and 
USH2A. Interestingly, Sloan-Heggen et al (2016) reported the p.(Ala163Val) allele in a patient 
with congenital hearing loss; however, this was in a compound heterozygous state with a 
second CLDN14 allele (p.Pro28Leu). In summary, these studies suggest that the likely 
pathogenic CLDN14 p.(Ala163Val) allele is both rare and widely distributed around the globe. 
Many reports claim that approximately 50% of autosomal recessive deafness is caused 
by either homozygous or compound heterozygous variants in the DFNB1 locus (GJB2). Given 
that targeted NGS hearing loss panels have recently been implemented in the clinic with GJB2-
negative cases, this represents a potential ascertainment bias, as children who been previously 
tested for DFNB1 only typically were not offered any additional genetic testing. Recently, a 
large, ethnically diverse, cohort study demonstrated the importance of investigating DFNB1-
negative deaf probands(Yan et al., 2016). This study took a targeted panel approach in 342 
probands (185 simplex and 157 multiplex families), sequenced 180 known hearing loss genes, 
and identified 151 variants in 119 families. Fifty-three families had pathogenic or likely 
pathogenic variants within 27 genes, while the remaining were variants of uncertain 
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significance. This study solved 25 and 7% of multiplex and simplex families, respectively, 
emphasizing the importance of large families and strong histories of disease in genetic 
studies(Yan et al., 2016). 
Pediatric hearing programs strive to identify and treat early in order to prevent delays in 
language, learning and social development. However, the detection of non-congenital and 
progressive forms of hearing loss remain a significant challenge. Children who are 
homozygous CLDN14 p.(Ala163Val) pass newborn and early hearing tests. The proband’s son 
(R2010, PID VI-4) was discharged after his normal hearing test at 1 year of age. Preschool 
testing 4 years later showed significant deterioration of both mid and high frequencies (Figure 
2.1c). Delayed identification could result from incomplete testing of high frequencies in the 
preschool years, often complicated by limited testing tolerance in children. In this study, PID 
VI-2 had normal hearing at 8 kHz at 2 years of age. At 3 years, hearing was reported normal, 
although thresholds at 8 kHz were not performed. By 4 years, this child had developed a 55 dB 
HL threshold at 8 kHz and mild to moderate loss at all high frequencies required immediate 
hearing aid fitting. Retrospectively, if 8 kHz thresholds had been performed at 3 years, 
diagnosis and therapy could have been offered one year earlier. Conversely, genetic testing or 
prenatal/preconception parental carrier screening would have allowed appropriate hearing 
surveillance and minimized the risk of delays in language development and learning from 
hearing loss.  
Adults who are homozygous for CLDN14 p.(Ala163Val) also have a consistent 
phenotype, but there remain challenges in management. Hearing aids benefit affected children 
and young adults (up to the third decade), but most adults do not find them beneficial. For 
example, PIDs V-9 (age: 50), V-10 (age: 51) and V-17 (age: 57) reported some additional 
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sound with hearing aids, but no improvement of speech comprehension, consistent with the 
extreme erosion of mid and high frequencies. Older affected adults with well-preserved low-
frequency sensitivity have limited ability to communicate by phone. PIDs V-10 and V-17, 
whose threshold at 0.5 kHz has deteriorated, can no longer communicate by phone. Adult 
members of this clan are highly skilled speech readers who can detect speech initiation and turn 
quickly to maximize the use of visual clues. Unfortunately, these skills can be mistaken for 
hearing and subjects have voiced concerns regarding safety in the workplace(Griffin, Personal 
communication: Discussion on hearing loss in NL. October 2018). 
The development of the organ of Corti is unidirectional, and follows a base-to-apex hair 
cell degeneration in the Cldn14-null mouse cochlea. This may explain why we observe a 
sensorineural threshold loss progressing from the high to low frequencies in affected clan 
members. The cochlea discerns high- from low-frequency sound, based on a stiffness gradient 
along the basilar membrane(Ehret, 1978; Teudt & Richter, 2014). In Cldn14-null mice, the 
organ of Corti undergoes a base-to-apex deterioration beginning around postnatal day 10, with 
a more severe and rapid degeneration of outer hair cells compared to inner hair cells. By day 
13, the three rows of outer hair cells are almost completely absent in the cochlear base, with 
partial loss and stereociliar disorganization in the middle and apical turns(Ben-Yosef et al., 
2003). The cochlear lesion then proceeds towards the cochlear apex, with a rapid deterioration 
of the outer hair cells accompanied by the onset of inner hair cell damage. By day 18, outer hair 
cell deterioration is severe with only a few remaining outer hair cells exhibiting damaged 
stereocilia in the most apical region; in contrast, only partial inner hair cell loss is reported 
throughout the cochlea by this age. Auditory brainstem responses measured in 4-week-
old Cldn14-null mice indicate a significant hearing loss, in comparison to their wild-type and 
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heterozygous littermates(Ben-Yosef et al., 2003). Since CLDN14 p.(Ala163Val) causes a 
precipitous mid/high frequency hearing loss with normal hearing thresholds in the lower 
frequencies, these findings are consistent with hearing phenotypes observed Cldn14-null mice. 
 
2.8 Summary 
A population-based study of hearing loss in the NL population has clarified the role 
of CLDN14 p.(Ala163Val), a VUS previously identified in the USA, Iceland and 
Sweden. CLDN14 p.(Ala163Val) appears to be of Irish origin and causes a precipitous, 
prelingual autosomal recessive form of non-syndromic sensorineural hearing loss. This likely 
pathogenic variant is frequent in this island population of Northern European decent. CLDN14 
p.(Ala163Val) homozygotes have normal hearing thresholds at birth, and then experience rapid, 
progressive hearing loss in early childhood. Although missed by newborn hearing screening, 
genetic testing would ensure identification of at-risk children, allowing for appropriate 
monitoring and timely intervention, aural rehabilitation and counselling for families. We 
recommend the inclusion of CLDN14 screening in NL newborn screening protocols for 
children with a family history of hearing loss.  
 
2.9 Limitations 
While exome sequencing is a powerful tool for elucidating disease-causing, coding 
variants, it does not explore non-coding regions. Additionally, there is no experimental proof of 
the predicted amino acid substitution, and without functional data, we cannot be certain that 
CLDN14 p.(Ala163Val) impacts protein localization within tight junctions. For example, this 
variant could cause alternative splicing or alter gene expression. Although less likely, it is 
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plausible that a causal, non-coding variant at the DFNB29 locus is in linkage disequilibrium 
with p.(Ala163Val). Even though our study presents several lines of evidence to suggest 
pathogenicity, experimental functional analysis of p.(Ala163Val) is required. 
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Hearing loss is the most genetic of all human phenotypes, and extremely genetically and 
clinically heterogeneous. In the current era, all Mendelian disorders are being solved at an 
accelerated pace, due to the routine use of whole exome sequencing. However, and particularly 
for hearing loss, new gene discoveries in dominant disorders lag behind. Herein, we report a 
six-generation family of Northern European ancestry with mid-high frequency (cookie bite) 
hearing loss progressing to a flat loss across all frequencies. In addition to cases of congenital 
hearing loss, some family members exhibit variable onset, progression and audiogram 
configuration. Linkage and haplotype defined the critical disease region to 769 Kb residing 
within the unsolved DFNA33 locus on chromosome 13q34. Whole exome and segregation 
analysis failed to identify the causative gene. Whole genome sequencing yielded several 
potential candidate variants, including ATP11A c.*11G>A, a medium impact variant predicted 
to cause the activation of a cryptic donor splice site. So far, ATP11A has 17 reported isoforms. 
RNA analysis on control tissues yielded three distinct bands and on patients yielded three extra 
high molecular bands not seen in control tissue, for a total of six bands. The three higher 
molecular weight bands all contained the insertion of 153bp contiguous segment of intronic 
sequence, resulting in the extension of exon 29 (in isoform ATP11A-201) and exon 30 (in 
isoforms ATP11A-202/212). This is the first description of mutations in the ATP11A gene 





Hereditary hearing loss is a common sensory disorder that exhibits extensive genetic 
and clinical heterogeneity(Morton & Nance, 2006). So far, over 200 hearing loss genes have 
been identified(Van Camp G, 2015); however, approximately one-third of the 60 mapped 
dominant loci have evaded discovery. Dominant hearing loss is typically characterized by 
variable expressivity and reduced penetrance(Richard JH Smith, 1999 ), making diseases genes 
particularly challenging to identify. In addition to the rarity of large extended families, there are 
thousands of loci heterozygous in individuals, making it almost impossible to solve without 
multiple, multigenerational families for study(Sherry et al., 2001).  Furthermore, using 
advanced bioinformatics that does not exclusively rely on the RefSeq database for sequence 
read alignment has been shown to be more robust at identifying causal variants, especially for 
the vast majority of genes represented by multiple isoforms(Belkadi et al., 2015; Zhao & 
Zhang, 2015) . 
A key feature of eukaryotic membranes is the non-random distribution of phospholipids, 
an essential feature to maintaining the integrity of a cell(Segawa et al., 2014). This non-random 
asymmetry is most evident at the plasma membrane(Zachowski, 1993) and is maintained by the 
action of three classes of proteins: scamblases, floppases and flippases. Phospholipid flippases 
(or P4-ATPases) specifically transport or “flip” of phospholipids from the outer to the inner 
leaflet of a phospholipid membrane(Paulusma & Elferink, 2010). Mouse studies have shown 
the importance of the P4-ATPase class of flippases in phospholipid metabolism and biology 
and in maintaining normal auditory function(Coleman et al., 2014; Stapelbroek et al., 2009). 
Furthermore, pathogenic variants in other P4-ATPases disease that encompass a hearing 
component., For example, ATP8B1 (MIM: 605868), cause intrahepatic cholestasis type 1 
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(MIM: 211600), where patients sporadically develop hearing loss(Stapelbroek et al., 2009). 
Moreover, phospholipids have been implicated in autoimmune conditions, such as 
antiphospholipid syndrome, a disorder characterized by the presence of antiphospholipid 
antibodies that invoke an autoimmune response, causing thrombosis, complications during 
pregnancy and hearing loss(Mouadeb & Ruckenstein, 2005; Wiles et al., 2006).  
 Herein, we describe a pathogenic splicing variant in ATP11A (MIM: 605868) that 
causes autosomal dominant hearing loss in a multiplex family from a genetic isolate, 
documenting the first disease association for this gene.  
 
3.4 Materials and Methods 
3.4.1 Study participants and clinical evaluations  
This project is a part of a large hereditary hearing loss study in NL, Canada. Informed 
consent, permission to access medical records and family history data were obtained from all 
research participants, as per approved institutional review board protocol #01.186 (Human 
Research Ethics Board, St. John’s, NL, Canada). Family R2070 has a history of bilateral, 
sensorineural hearing loss spanning five generations (Figure 3.1).  
Hearing loss was measured using air conduction thresholds and pure-tone audiometry 
methods noting severity progression and severity. The proband (PID IV-7; Figure 3.1) 
exhibited a progressive, sloping, bilateral sensorineural hearing loss (Figure 3.2A), and hearing 
severity was variable across 18/25 recruited members that were affected in this autosomal 
dominant pedigree (Figure 3.2B-D). Although the age of onset ranged between the first and 















































































































































































































































































































































































































































































































































































































































































3.4.2 Targeted screening and linage analysis 
Preceding to this study, genomic DNA was extracted from peripheral blood using a 
simple salting out protocol(Miller et al., 1988). The Family R2070 proband PID IV-7, Figure 
3.1) was screened for population-specific deafness alleles (Appendix C; Abdelfatah, 
McComiskey, et al., 2013; Abdelfatah, Merner, et al., 2013; Ahmed et al., 2004; Doucette et 
al., 2009; Young et al., 2001). To identify candidate hearing loss genes, we submitted 
audiometric data from the proband to Audiogene (v4.0), a computational algorithm comparing 
sample audiograms to reference audioprofiles of 34 autosomal dominant deafness 
loci(Hildebrand et al., 2009). Next, genome-wide single nucleotide polymorphism (SNP) 
genotyping was performed using the Illumina 610Quad genotyping chip (Illumina Inc., San 
Diego, CA, USA) on select family members. Starting with a set of >500,000 high quality SNP 
markers, a subset of informative markers (n=17,407) was used for parametric two-point linkage 
analysis using Superlink (v1.7)(Fishelson & Geiger, 2004). Linkage analysis was performed 
under an autosomal dominant model with 99% penetrance and a disease allele frequency of 
0.0025. Genomic DNA on all available family members was extracted from peripheral blood 
using a modified salting out protocol(Miller et al., 1988). 
 
3.4.3 Whole exome sequencing (WES) and variant filtration 
We prepared whole exome libraries for four affected (PID IV-4, IV-6, IV-7, and IV-12;) 
and two unaffected (PID IV-1 and IV-17; Figure 3.1) family members with the Ion Torrent 
AmpliSeq RDY Exome Kit (Life Technologies, Cat. #A27193), followed by purification, 
adapter ligation and barcoding using the Ion PI Hi-Q OT2 200 kit (Life Technologies, Cat. 
#A26434). Exome libraries were quantified using the Ion Library Quantification Kit (Life 
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Technologies, Cat. #4468802) and then loaded onto a PI v3 chip and sequenced with the Ion 
Torrent Proton Sequencer. Geoff Woodland called and annotated SNVs and IDELS using 
GATK (v3.5) and SnpEff (v4.1; http://snpeff.sourceforge.net/), respectively. Subsequently, 
variants were filtered variants against publically available SNP databases (ExAC 
Browser, http://exac.broadinstitut-e.org/; dbSNP, http://www.ncbi.nlm.nih.gov/projects/SNP/; 
1000 genomes, http://www.1000-genomes.org) and the impact of SNVs at the protein level was 
assessed using SIFT, PolyPhen-2, and MutationTaster. In addition, moderate and high impact 
variants (nonsense, frameshift, missense, splice sites) with a minimum of 30X coverage were 
included in our final list of candidate variants. Given that the family has a clear autosomal 
dominant inheritance pattern, we filtered for heterozygous variants that were shared across all 
affected family members and absent in unaffected members. Two separate analyses were 
conducted. First, we filtered for rare variants that had a MAF of <1%. Our second analysis 
included the filtration of common variants that have a MAF <10%, given that we have 
previously identified a common pseudodominant hearing loss allele (CLDN14 c.488C>T) in the 
NL population. Sequencing coverage within our linked regions was assessed and any genes that 
did not meet our variant filtration criteria were manually sequenced.  
 
3.4.4 Comprehensive audioprofiling 
 Given that no variants that were identified by WES, we considered that this may be due 
to a mutation that exhibits reduced penetrance or perhaps there are phenocopies in this family. 
Therefore, we (JAP and AG) decided to conduct an extensive audioprofile analysis on all 
available family members. This comprehensive exercise ensured that we were selecting family 
members with the most similar phenotypes for WGS. 
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3.4.5 Whole genome sequencing and variant filtration 
 Genomic DNA libraries were prepared on four affected (PID IV-4, IV-6, IV-7, and IV-
12) and two unaffected relatives (PID IV-1 and IV-17) using the Lucigen Shotgun NxSeq 
AmpFREE Low DNA Library Kit (Cat. #14000-1, Lucigen Inc., Madison, WI, USA). Prepared 
libraries were loaded on an Illumina paired end 150 base pair (bp) sequencing lane, and 
sequenced on the HiSeqX Sequencer (Illumina Inc., San Diego, CA, USA). Sequence reads 
were aligned to GRch37 in both RefSeq and Ensembl reference genomes, and single nucleotide 
variants (SNV) and insertions and deletions (INDELs) were called using GATK (v4.0). 
Structural chromosomal variants were called using Lumpy (v0.2.13) and SVtyper (v0.5.2), 
while a Bioconductor package, cn.MOPS (v1.26.0), was used for copy number variation (CNV) 
analysis. Variants were functionally annotated with SNPeff (v4.3T). We filtered for rare 
variants using a MAF <1% with a minimum of 20X coverage in genes residing within the 
linked regions.  
 
3.4.6 Cascade sequencing, segregation and haplotype analysis 
Candidate variants were amplified using a standard touchdown PCR protocol and 
sequenced in all available family members and 326 ethnically-matched controls to determine 
the MAF. Haplotype analysis was performed using microsatellite markers and intergenic SNPs. 
Genotyping was performed using GeneMapper software (v4.0) and while SNVs were 
sequenced in all available family members(Pater et al., 2017). Subsequently, genotypes were 
phased across the family pedigree. Microsatellites were genotyped according to standard 
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procedures(Abdelfatah, McComiskey, et al., 2013) using GeneMapper software (v4.0) and 
haplotypes were reconstructed manually.  
 
3.4.7 Experimental validation of splicing variants 
Candidate splicing variants within exon-intron boundaries were analyzed in silico using 
MaxEnt, Human Splicing Finder (v3.1), and NNSPPLICE (v0.9) to determine their effects on 
RNA splicing, which were experimentally validated using RNA from transformed patient-
derived B-cell lymphocytes. RNA was extracted using TRIzol-based methods (Thermo-fisher, 
Cat. #15596026) and cDNA libraries were prepared with the Superscript VILO cDNA synthesis 
kit (Thermo-fisher, Cat. #11754050) followed by genomic DNA digestion using the Turbo 
DNA-free kit (Invitrogen, Cat. #1907). Reverse transcription PCR (RT-PCR) was performed 
using a standard touchdown PCR protocol and primers that flanked candidate splicing variants 
(ATP11A: 5’ CCAGAGGGGTGTGAAGCA 3’ and 5’ CATCACACGAGCATTCCCAC 3’; 
COL4A1: 5’ GTTCACCTGGCTTACCTGGA 3’ and 5’ AAACCCACCTCACCCTTTG 3’). 
RT-PCR products were visualized using a 1.5% agarose Tris-Borate-EDTA gel stained with 
SYBR Safe (Invitrogen, Cat. #S33102). We employed TA-cloning technology using the TOPO 
TA-Cloning Kit for Sequencing with One Shot TOP10 Chemically Competent E. coli 
(Invitrogen, Cat. #K457540) according to the manufacturer’s protocol, for candidate genes with 
multiple transcripts (Appendix D). Clones were amplified using colony PCR(Costa & Weiner, 
2006), sequenced and visualized using Mutation Surveyor Software (v5.0, SoftGenetics LLC 




3.5.1 Hearing loss maps to 13q34 overlapping with the DFNA33 locus 
The proband screened negative for all known pathogenic hearing loss variants in the 
Newfoundland (NL) population (Appendix C), prompting a more comprehensive genomic 
approach. SNP genotyping and linkage analysis identified a 3.6 Mb region at 13q34 (chr13: 
110,708,368-114,312,000; Appendix E) with a LOD score of 4.77, overlapping with 
DFNA33(Bonsch et al., 2009).  
 
3.5.2 Whole exome sequencing fails to identify the genetic basis of hearing loss  
 In total, 40 variants were identified in four affected family members (PID IV-4, IV-6, 
IV-7, IV-12) and were absent two unaffected members (PID IV-1 and PID IV-17; Figure 3.1). 
After the removal of likely false positive and known benign calls, our first analysis identified 
10 rare variants (<1% MAF) in four affected family members (Appendix F). Accounting for the 
possibility of reduced penetrance and pseudodominance, our second analysis identified an 
additional 12 common variants (1%-10% MAF; Appendix G). Between both analyses, 9 of 
these variants resided on chromosomes that were identified by our linkage analysis. One 
common variant, CARS2 c.538A>T (rs72661692, MAF = 7.37%) was identified within our 
linked region on chromosome 13. However, it failed to segregate with hearing loss. All 10 rare 
variants were tested for segregation (Appendix H), but also did not segregate with hearing loss 
in the family. We decided that testing for segregation on common variants that did not reside in 
our linked region on chromosome 13 was a waste of resources, and therefore, these variants 
were not sequenced. All genes within our linked region met our coverage criteria for variant 
filtration, with the exception of two very small genes, SOX1 (MIM: 602148) and IRS2 
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(MIM:600797). Upon reviewing these genes in UCSC Genome Browser (https://genome 
.ucsc.edu/), it was discovered that both of these genes contain >75% GC content, which 
explains why there had no coverage during WES. In order to overcome this challenge, we 
manually amplified SOX1 and IRS2 using 16 primer sets that covered all coding regions of 
these genes, followed by Sanger sequencing. While these data revealed several benign 
polymorphisms that are present in the global population in high numbers, no deleterious 
variants were identified (data not show).  Consequently, comprehensive audioprofiling analysis 
was performed to determine if there were any potential phenocopies in the family (Appendix I). 
A detailed report was generated, which was crucial in deciding on what samples to use for 
whole genome sequencing and how to interpret genomic results in this family (Appendix J).  
 
3.5.3 Two candidate genetic variants co-segregate with dominant hearing loss 
Comprehensive audioprofiling confirmed that PID IV-4, IV-6, IV-7, IV-12 and PID IV-
1 and PID IV-17 (Figure 3.1), were the most representative family members that were affected 
and unaffected, respectively (Appendix I and J). An average coverage of 44X was obtained 
with 94% of the genome covered at 25X. A total of 15,071 variants (minimum of 20X 
coverage) were identified in four affected family members and absent in two unaffected 
members, with 49 low impact and two medium impact rare variants (<1% MAF) residing 
within the linked 3.6 Mb region (Table 3.1). No structural chromosomal rearrangements or 
CNVs were identified (data not shown). Two candidate splicing variants in ATP11A 
(c.*11G>A; ATP11A-203; ENST00000415301.1; Figure 3.3) and COL4A1 (c.3326-7dupT; 
NM_001845; rs532261610; Figure 3.4) co-segregated with the disease-associated haplotype 




























































































































































































































































































































Figure 3.3. Sequence electropherogram illustrating the ATP11A c.*11G>A substitution. Red 














Figure 3.4. Sequence electropherogram COL4A1 c.3326-7dupT variant. Red arrow indicates 
site of the heterozygous duplicated T. 
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(ENST00000415301.1; GERP: 5.160; CADD: 12.03), whereas COL4A1 c.3326-7dupT medium 
impact variant (ENST00000375820.8; GERP: 2.860; ExAC: 0.002314; GnomAD: 0.00245815) 
has a 0.25% MAF. Both of these variants are absent in 326 ethnically-matched population 
controls. Importantly, two recombinant family members (PID III-4 and V-2; Figure 3.1) were 
recruited during the transcriptional analysis of the two splicing variants. Separate crossing over 
events occurred between COL4A1 c.1221-18G>A and D13S285 (PID III-4), and D13S1295 and 
ATP11A c.*11G>A (PID V-2), which reduced the critical region to 769 Mb and excluded 
COL4A1 from the disease haplotype. Several in silico tools predict that COL4A1 c.3326-7dupT 
does not disrupt splicing, which was confirmed by RNA analysis (Figure 3.5). Consequently, 
this variant was not further investigated. 
 
3.5.4 RNA analysis reveals multiple ATP11A transcripts   
The ATP11A variant was identified as a medium impact variant in exon 2 of ATP11A-
203. This transcript is poorly supported by a suspect EST and has an incomplete annotation of 
the 5’ coding (CDS) sequence. In total, the ATP11A gene encodes 17 transcripts (Human 
GRCh38.p12 Ensembl 93 build(Yates et al., 2016)), most of which are incompletely annotated 
and includes two RefSeq transcripts: 8,768 bp isoform b (ATP11A-201 ENST00000375630.6; 
NM_032189) and 8,795 bp isoform a (ATP11A-202 ENST00000375645.7; NM_015205). 
Given that in silico algorithms predicted that the ATP11A variant functionally disrupts a 
canonical donor splice site (Table 3.2), we performed RT-PCR with ATP11A-203-specific 
primers on EBV-transformed B-cell lines from peripheral blood of three controls (wild-type) 
and three affected ATP11A-203 c.*11G>A carriers (PID III-1, III-5 and III-7; Figure 3.1). 




Figure 3.5. COL4A1 c.3326-7dupT RNA Analysis. RT-PCR amplification in affected R2070 
family members (PID III-1, III-5, and III-7) and wild-type controls. Despite our in silico 
analyses predicting that COL4A1 c.3326-7dupT would not alter splicing, we felt it was 
necessary to experimentally validate this prediction in order to confidentially exclude this 
variant. As expected, COL4A1 c.3326-7dupT RT-PCR experiments amplifies a single amplicon, 




Table 3.2. In silico predictions for ATP11A, chr13:113534962G>A 
Allele Reference Alternate Difference 
MaxENT 6.43 1.43 5 
Human Splice Finder 70.8 41.85 28.95 
Maximum Dependence 
Decomposition Model 10.08 3.98 6.1 
First-order Markov Model 5.09 1.41 3.68 




(Figure 3.6). Subsequent cloning revealed three bands in controls (1x~300 bp; 2x~370 bp) and 
three additional bands (1x~500 bp; 2x~550 bp) in the ATP11A c.*11G>A carrier (PID III-1; 
Figure 3.7). Sanger sequencing of the common lower molecular weight bands of ATP11A-203 
transcript showed that the clones map to three alternatively spliced full-length transcripts: 
ATP11A-201 (Figure 3.8), ATP11A-202 (Figure 3.9) and ATP11A-212 (ENST00000487903.5; 
Figure 3.9). These data identify a missing exon from the open reading frame in the current 
ATP11A-201 and in the 3’UTR of ATP11A-202/212 Human (GRCh38.p12) Ensembl 93 
build(Yates et al., 2016). The cloning experiments indicate that the 104 bp exon (ATP11A-203) 
is likely the true previously uncharacterized exon in ATP11A-201 and ATP11A-202/212, 
preserving the 3’ end of each transcript (Figure 3.8b & 3.9b). In one of the two RefSeq 
transcripts (ATP11A-201; Figure 3.8a), the addition of the missing exon (104 bp) is spliced to 
the 3’ end of exon 28 revealing that the true stop codon (TAG) is located 159 bp upstream of 
the reported stop codon (Figure 3.8b). RefSeq transcripts (ATP11A-202/212; Figure 3.9a) have 
the missing exon (104 bp) spliced to the 3’ end of exon 29, extending the 3’UTR (Figure 
3.9b,d,e). Consequently, the c.*11 variant in exon 2 of ATP11A-203 is located at the same 
position in ATP11A-201 but positioned at c.*113 in ATP11A-202/212. 
 
3.5.5 A pathogenic ATP11A splicing variant activates a cryptic donor splice site 
 According to splicing analyses, the ATP11A variant is predicted to activate a cryptic 
splice site 153 bp downstream of the canonical donor splice site. After correcting the annotation 
of the RefSeq transcripts, the composition of the three additional low molecular weight 
transcripts reveal that the variant of interest resides in the 3’ boundary of exon 29 of ATP11A-























Figure 3.6. ATP11A RT-PCR. Amplification in affected R2070 family members (PID III-1, III-














































Figure 3.7 Colony PCR amplification of TA-cloned  RT-PCR amplification in affected R2070 













































































































































































































































































































































































































































































































































aberrant higher molecular weight bands (Figure 3.7) in the ATP11A c.*11G>A/*113G>A 
carrier revealed that all contain the same 153 bp intronic sequence extending exon 29 (ATP11A-
201; Figure 3.8e) and exon 30 (ATP11A-202/212; Figure 3.9f & g) experimentally confirming 
in silico prediction. 
 
3.6 Discussion  
We report a pathogenic splicing variant in the ATP11A gene that maps within the 6cM  
disease interval as the DFNA33 locus (13q34), as first described by Bönsch et al(Bonsch et al., 
2009). ATP11A c.*11G>A carriers in the family were diagnosed with low to mid frequency 
hearing loss during the first decade progressing to a sloping configuration. Two key critical 
recombination events on the disease-associated haplotype in unaffected relatives excluded all 
but a medium impact variant in ATP11A. Other P4-ATPase members are associated with 
syndromic forms of hearing loss and this study documents the first association of ATP11A with 
a highly penetrant Mendelian phenotype. The hearing loss in the 4 generation German family 
that map DFNA33 exhibits similar audioprofiles, progressing to a flat hearing loss across all 
frequencies. Although we cannot be certain that ATP11A is DFNA33, it was noted by Bönsch et 
al to be a functional candidate based on mouse studies. (Bonsch et al., 2009) Although a decade 
has passed since DFNA33 was mapped to chromosome 13q34-qter, no other families have been 
reportedly mapped to this locus.  
 This study highlights the importance of combining whole-genome sequencing, a 
comprehensive bioinformatics pipeline targeting all known transcripts and experimentally 
validating genomic findings in patient tissues. Using Ensembl, of the 17 annotated ATP11A 
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transcripts, we mapped the PCR amplicon containing the putative mutation to a short, poorly 
supported, isoform containing 3 exons total. However, downstream cDNA analysis in 
transformed white blood cells identified 3 long isoforms in control and patient samples. The 
ATP11A c.*11G>A carriers also had 3 additional high molecular weight isoforms. Cloning 
experiments suggest that the 104 bp exon (ATP11A-203) likely represents the true previously 
uncharacterized exon in ATP11A-201/202/212 that is unreported in Ensembl 93 build(Yates et 
al., 2016). Our pathogenic ATP11A variant destroys the canonical door splice site, activating a 
cryptic donor splice site 153 bp downstream. Though, the disease mechanism underlying the 
insertion of 153 bp into the 3’ UTR of ATP11A is unclear. Given that the splicing variant is 
located in 3’UTR, it is unlikely that it affects protein structure; however, it might affect protein 
function through modulating ATP11A gene expression at the post-transcriptional level. The 
poor annotation of some of the ATP11A transcripts made it difficult to assess the effect of the 
variant on the mature RNA. The availability of tissue samples from affected and unaffected 
within the family and the multiplex pedigree structure were critical resources that helped to 
discern the altered RNA species expressed in the disease state.   
A recent study demonstrated that there could be as little as 19,000 protein coding gene 
in the human genome(Ezkurdia et al., 2014). While less than 200 genes are tissue specific(Mele 
et al., 2015), it has been estimated that there is at least 205,000 protein-coding transcripts in the 
human genome(Hu et al., 2015). One reason as to why we think this family remained unsolved 
until now is due to whole exome sequencing capture bias in primitive capture systems. The Ion 
Torrent AmpliSeq RDY Exome Kit systems is PCR-based and designed to capture 97.5% of 
genes contained within the Consensus CDS (CCDS) project(Damiati et al., 2016),(O'Leary et 
al., 2016; Wang et al., 2017). Not only does this WES method create PCR amplification 
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bias(Aird et al., 2011), it neglects transcripts that are not within the CCDS project(Damiati et 
al., 2016), which misses an estimated 3% of coding variants and the majority of the over 8 
million ESTs(Belkadi et al., 2015; dbEST, 2019; Nagaraj et al., 2007). In contrast, our WGS 
approach utilized a shotgun, PCR-free capture system that minimizes PCR-biases. This 
approach captures >98% of the entire genome and has been shown to be more robust in 
identifying causal variants during exploratory research(Belkadi et al., 2015). In retrospect, we 
evaluated coverage and read-depth of ATP11A, and according to Ion Torrent metrics, all coding 
regions of this gene met our specified quality score values for variant filtration. Therefore, the 
Ion Torrent AmpliSeq RDY exome system must lack probes that amplify the coding regions of 
ATP11A-203 and may explain why our ATP11A variant went undetected during our WGS 
analyses. Given that WGS identified a variant in an ATP11A exon that was previously unknown 
to the RefSeq database, this speaks to the complexity of the human transcriptome.  
The ATP11A gene encodes for an integral membrane P4-ATPase, a phospholipid 
flippase that specifically catalyzes the energy dependant transport or “flip” of phospholipids 
from the outer to the inner leaflet of a phospholipid membrane(Paulusma & Elferink, 2010). 
While 14 P4-ATPase are annotated in the human genome, many are functionally 
related(Paulusma & Elferink, 2010; van der Mark et al., 2013). For example, ATP11A, 
ATP11C, ATP8A1, and ATP8A2 specifically utilize phosphatidylserine (PS) as a substrate(Lee 
et al., 2015; Takatsu et al., 2014). These P4-ATPases ensure that the outer leaflet of the plasma 
membrane is devoid of PS, which acts as an phagocytic “eat me” signal for in cells undergoing 
apoptosis when presented at the cell surface(Segawa et al., 2014).  Impressively, Segawa et 
al(Segawa et al., 2016; Segawa et al., 2014) have demonstrated that ATP11A and ATP11C are 
the major flippases of mammalian cells and the loss of ATP11A results in PS presentation at the 
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cell surface, in vitro; however, other P4-ATPases, such as ATP11C, possess redundant 
compensatory roles. We propose that ATP11A haploinsufficiency leads to aberrant increase 
phagocytic signals due to increased PS levels at the surface of many cells of the auditory 
system (Figure 3.10). Additionally, the genetic background of compensatory epistatic factors 
that regulate the expression of other P4-ATPases must be considered. Given that our ATP11A 
variant is specific to 3 of 16 ATP11A transcripts, perhaps other transcripts are sufficient to 
maintain normal physiology across the body, as well as maintaining normal hearing during the 
first decade. 
Mouse investigations that explore the role of P4-ATPases, such as Atp8b1 and Atp8a2, 
demonstrate that these genes assimilate their human phenotype counterparts, including auditory 
deficits. Coleman et al(Coleman et al., 2014) found severe visual and auditory system defects 
in Atp8a2-defiecient mice. Despite having intact sensory hair cells, Atp8a2 knockout mice 
exhibit reduced auditory startle responses. Relative to wild-type mice, auditory brainstem 
responses and light microscopy in 2-month-old Atp8a2-deficient mice identified significantly 
higher hearing thresholds at 16 kHz and a marked reduction in the number of spiral ganglion 
cells in cross sections through the basal turns of cochlea, respectively. This finding is 
conceivable, as both the auditory and visual systems have been implicated in other human 
phenotypes, such as Usher syndrome(Keats & Corey, 1999). Another study has found that 
ATP8B1 is essential for maintaining normal hearing(Stapelbroek et al., 2009). This intrahepatic 
cholestasis mouse model harbored a homozygous missense variant, Atp8b1G308V/G308V, which 
significantly decreased Atp8b1 expression in mice(Pawlikowska et al., 2004), and resulted in 
hair cell degeneration and abnormal auditory brainstem responses at 1, 3 and 6 



































































































































































































































































































Future directions include the quantitative analyses of ATP11A splicing variant, in 
addition to loss in vitro and in vivo functional characterization of the molecular mechanisms. 
Phagocytic signals, such as PS at the cell surface, are known pharmaceutical targets(Birge et 
al., 2016), so there is potential that hearing loss due to ATP11A could be mitigated, especially 
since there is a brief therapeutic in those affected by non-congenital hearing loss. In order to 
functionally characterize our ATP11A splicing variant, several biological assay would be 
required. Firstly, a dual luciferase assay would demonstrate that defects would silence this gene 
at the post-transcriptional level. Briefly, two different luciferase assays would be performed – 
one group would have a wild-type ATP11A 3’UTR, while the other group would have our 
mutant ATP11A 3’UTR. Conceptually, the wild-type group would produce robust luciferase 
fluorescence, whereas the mutant group would exhibit a reduced signal. These findings would 
indicate that the cryptically spliced mutant ATP11A 3’UTR harbours miRNA sites that are not 
present in its wild-type counterpart. Subsequently, generating CRISPR-Cas9 ATP11A null HEI-
OC1 cells (mammalian auditory sensory hair cell line) would enable researchers to determine 
the biological consequences of the loss of ATP11A. Since ATP11A is known to translocate PS 
to the inner leaflet of the plasma membrane, immunofluorescence would indicate the 
cytological location of PS in ATP11A-null HEI-OC1 cells. In addition, given that aberrant PS 
presentation at the cell surface induces apoptosis, a combination of immunoblotting for cleaved 
caspase-3 and TUNEL assays in wild-type and ATP11A-null HEI-OC1 cells would indicate 
whether programmed cell death was imminent. Assuming that these hypotheses held true, the 
final step would be to investigate the atp11a-null mouse, which is currently cryopreserved at 
The Jackson Laboratories in Bar Harbour, Maine, USA.  
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Background: Usher syndrome, the most common form of inherited deaf-blindness, is unlike 
many other forms of syndromic hereditary hearing loss in that the extra aural clinical 
manifestations are also detrimental to communication. Usher syndrome patients with early 
onset deafness also experience vision loss due to progressive retinitis pigmentosa that can lead 
to legal blindness in their third or fourth decade. Methods: Using a multi-omic approach, we 
identified three novel pathogenic variants in two Usher syndrome genes (USH2A and ADGRV1) 
in cases initially referred for isolated vision or hearing loss. Results: In a multiplex hearing loss 
family, two affected sisters, the product of a second cousin union, are homozygous for a novel 
nonsense pathogenic variant in ADGRV1 (c.17062C>T, p.Arg5688*), predicted to create a 
premature stop codon near the N-terminus of ADGRV1. Ophthalmological examination of the 
sisters confirmed typical retinitis pigmentosa and prompted a corrected Usher syndrome 
diagnosis. In an unrelated clinical case, a child with hearing loss tested positive for two novel 
USH2A splicing variants (c.5777-1G>A, p. Glu1926_Ala1952del and c.10388-2A>G, 
p.Asp3463Alafs*6) and RNA studies confirmed that both pathogenic variants cause splicing 
errors.  Interestingly, these same USH2A variants are also identified in another family with 
vision loss where subsequent clinical follow-up confirmed pre-existing hearing loss since early 
childhood, eventually resulting in a reassigned diagnosis of Usher syndrome. Conclusion: 
These findings provide empirical evidence to increase Usher syndrome surveillance of at-risk 
children. Given that novel antisense oligonucleotide therapies have been shown to rescue retinal 
degeneration caused by USH2A splicing pathogenic variants, these solved USH2A patients may 




Approximately 30% of inherited hearing loss is syndromic and is classically 
characterized by overt clinical features, such as distinctive craniofacial and eye abnormalities, 
and joint problems as in Stickler syndrome (Baker et al., 2011; MIM: 108300). However, 
syndromic forms of hearing loss such as Usher syndrome (USH), present more insidiously, 
often resulting in delayed or misdiagnosis. USH is an autosomal recessive condition 
characterized by bilateral sensorineural hearing loss with or without vestibular dysfunction, and 
progressive retinitis pigmentosa (RP; Keats & Corey, 1999; Kimberling et al., 2010; Mathur & 
Yang, 2015). Most children with USH are born with congenital hearing loss; however, 
progressive RP may present in the second decade, making diagnosis difficult due to the subtle 
changes in visual function over time (Yan & Liu, 2010). Historically, USH was considered an 
extremely rare disorder with a frequency of 1 in 25,000 (Boughman et al., 1983); however, a 
recent study suggests a higher prevalence of 1 in 6,000 individuals in the European (Non-
Finnish) population (Kimberling et al., 2010). 
USH is an extremely deleterious disorder and is the most common cause of inherited 
deaf-blindness (Kimberling et al., 2010). So far, 13 USH genes have been identified which 
adversely affect the development of sensory hair cells within the inner ear and of 
photoreceptors in the eye (Yan & Liu, 2010). The most common subtype, USH type 2A 
(USH2A), accounts for two-thirds of all cases. Many USH2A pathogenic variants cause splicing 
defects such as exon skipping and the creation or destruction of canonical acceptor and donor 
splice sites (Yan & Liu, 2010). Novel therapies that target USH2A show great promise as retinal 
degeneration in USH2A patients can be rescued using antisense oligonucleotide-based therapy 
targeting cryptic splicing variants (Slijkerman et al., 2016). Additionally, antioxidant-based 
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therapies have also shown great promise in preventing cone degeneration in USH1 mice, which 
is linked to oxidative stress (Trouillet et al., 2018). Oxidative stress has well-established roles 
in many retinal dystrophies, where polymorphisms in GLO1 may explain RP susceptibility and 
clinical heterogeneity (Donato et al., 2018). Enrollment of patients in therapeutic trials requires 
a molecular diagnosis which can be challenging in the clinical setting. A comprehensive 
approach that includes linkage analysis, exome sequencing and functional analysis is often 
required, especially for novel splicing variants (Lewis et al., 2018; Sakuma et al., 2016).  
Herein, we report three novel USH pathogenic variants in USH2A or ADVRG1 identified in 
cases of vision and hearing loss using a comprehensive multi-omic approach. 
 
4.4 Materials and Methods 
4.4.1 Study Participants and Clinical Evaluations  
The study involved three families from the Newfoundland population, including two 
multiplex families. Clinical evaluations included air conduction thresholds using pure-tone 
audiometry, noting the audiogram configuration, severity, onset and progression. Vision was 
assessed with ocular examination, visual acuity and visual field testing, electroretinography 
(ERG) and fluorescein angiography of the retina.  
For Family R2100, hearing loss (HL) is present in three sibships with varying 
audioprofiles, including two sisters who are the product of a consanguineous union (Figure 
4.1). The proband (PID V-2) diagnosed with hearing loss at 3 years, presents by age 7 with a 
mild to moderate bilateral sensorineural HL, and her younger sister (PID V-3) was diagnosed at 






















Figure 4.1. Family R2100 Pedigree. This family is a hereditary hearing loss pedigree with three 

























Figure 4.2. Family R2100 Audiological Data. Serial audiograms from PID V-2 and V3 




We also recruited a case from our local medical genetics’ clinic (Family R4110; Figure 
4.3) of a child diagnosed at 3 months (following newborn hearing screening), who presents by 
age 3 with mild to moderate bilateral sensorineural HL (Figure 4.4). In another multiplex 
family (R0723), the proband and his brothers (PIDs II-5, II-3 and II-6, respectively) were first 
diagnosed with RP in mid 5th decade when their central vision decreased to the point that they 
met criteria for legally recognized blindness (Figure 4.5). They reported reduced night vision 
since the mid-second decade, and hearing loss since young childhood. The proband had been 
fitted for hearing aids for moderate to severe hearing loss. In R0273, the proband and his 
brothers (PIDs II-5, II-3 and II-6 respectively) had reported experiencing reduced night vision 
since their mid-third decade and were all diagnosed with RP in the mid-fifth decade when their 
central vision decreased. Throughout the course of ongoing clinical assessment, it was noted 
that the proband was fitted for hearing aids due to a moderate to severe HL and although the 
age of onset was unknown, he had HL at a young age. Two nieces with early hearing loss were 
also diagnosed with RP on follow-up, which prompted targeted genetic testing for known USH 
genes (Figure 4.4). 
 
4.4.2 Gene Panels 
In the case of family R0723, a targeted gene panel for 13 USH genes (CEI Molecular 
Diagnostic Laboratory, Portland, OR, USA) was offered through a research study on hereditary 
vision loss.  In the clinical case of the child who failed newborn hearing screening (Family 
R4110), the family was offered targeted screening (158 syndromic and non-syndromic hearing 
loss genes, Blueprint Genetics, Comprehensive Hearing Loss and Deafness Panel, version 1, 













Figure 4.3. Family R4110 Pedigree. This family was recruited through the Newfoundland 























Figure 4.4. Family R4110 and R0723 Audiological Data. Audioprofile of PID II-1 (R4110) and 





Figure 4.5. Family R0723 Pedigree. This Usher syndrome family was recruited through 
hereditary eye study.  
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and/or HL trait in the families, genomic DNA was amplified using custom primers and 
sequenced in both directions using standard touchdown PCR protocols (ABI PRISM 3500XL 
DNA Analyzer; Applied Biosystems, Foster City, CA, USA). Sequence traces were analyzed 
using Mutation Surveyor Software (version 5.00, SoftGenetics LLC State College, PA 16803). 
 
4.4.3 Linkage Analysis and Whole Exome Sequencing in Hearing Loss Family R2100 
We initially screened the proband of Family 2100 for deafness alleles previously 
identified in the NL population (Appendix C) and submitted representative audiograms to 
Audiogene, a program comparing these to average audiograms of 34 deafness loci (Taylor et 
al., 2013). As this targeted approach failed to solve Family 2100, traditional linkage study was 
done. For the linkage analysis, we selected three affected and two unaffected relatives (PID V-
2, V-3, III-9, and IV-3, IV-4 respectively; Figure 4.1) and genotyped 17,407 polymorphic 
markers with the Illumina Human610-Quad chip. Multipoint linkage analysis (Merlin v1.1.2) 
(Abecasis et al., 2002) was performed under a recessive model with a disease allele frequency 
of 0.07 and a penetrance of 99%. In order to screen candidate genes within linked regions, 
whole exome sequencing was carried out on 5 family members (two affected offspring and 
their parents: PID V-2, V-3, IV-3, IV-4 respectively) using the Ion Torrent AmpliSeq RDY 
Exome Kit (Life Technologies, Cat. #A27193). Purified libraries were loaded onto an Ion 
Proton PI v3 chip and sequenced with the Ion Torrent Proton.  Only rare variants (MAF <1%) 
that mapped to linked regions, had a depth of coverage >20X and were of medium to high 
impact were validated by Sanger sequencing and selected for cascade screening. Population 
frequencies were determined using 124 ethnically-matched controls. 
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4.4.4 Splice variant in silico analysis 
For variants of interest that reside within canonical +/− 1 or 2 splice sites, we conducted 
in silico analyses using Alamut Visual (Interactive Biosoftware Inc., Rouen, France), a program 
that provides a splicing alteration report by linking to the MaxEnt, NNSPPLICE, 
SplicSiteFinder, and GeneSplicer algorithms.  
 
4.4.5 RNA-cDNA analysis 
In order to experimentally validate splicing predictions, we extracted total RNA from B-
cell lymphocytes using standard TRIzol-based methods (Thermo-fisher, Cat. #15596026) and 
prepared cDNA libraries with the Superscript III First Stand Synthesis System (Thermo-fisher, 
Cat. #18080093). RT-PCR was carried out with primers that spanned candidate splicing 
regions, followed by TOPO TA-Cloning using One Shot TOP10 Chemically Competent E. coli 
cells (Invitrogen, #K457540) according to the manufacturer’s protocol. RT-PCR products were 
Sanger sequenced and then analyzed using Mutation Surveyor Software (version 5.00, 
SoftGenetics LLC State College, PA 16803). 
 
4.5 Results 
4.5.1 ADGRV1 c.17062C>T Genotype/Phenotype Analyses 
In the step-wise analysis of hearing loss Family 2100, the proband (PID V-2; Figure 
4.1) screened negative for all hearing loss variants previously identified in the NL population. 
Genome-wide linkage analysis (assuming autosomal recessive inheritance) yielded positive 
LOD scores suggestive of linkage for 8 genomic regions and the theoretical maximum LOD 





exome sequencing identified 278 variants that were shared between the proband (PID V-2) and 
her affected sister (PID V-3). Of these, only eight variants remained after filtering for rare 
variants (MAF <1%) of medium to high impact that mapped to linked regions and had a depth 
of coverage >20X (Table 4.2). Seven of these variants were shown to be false positive INDELs 
(did not validate with Sanger sequencing) or did not reside within genes associated with 
syndromic or non-syndromic HL (Van Camp G, 2015).  The remaining candidate (ADGRV1 
c.17062C>T; p.Arg5688*) is a nonsense variant associated with USH2C (Figure 4.6). Co-
segregation analysis confirmed that the affected sisters were homozygous for ADGRV1 
c.17062C>T and their parents were unaffected carriers (Figure 4.7).  The only other available 
affected relative for cascade sequencing was a maternal uncle (PID III-9) who was wild-type 
(two normal copies) and subsequently confirmed to have acquired his hearing loss after a 
serious diving accident. The nonsense ADGRV1 variant is predicted to create a premature stop 
codon nearing the N-terminus of ADGRV1, preventing the translation of all 7 transmembrane 
domains. Furthermore, the ADGRV1 c.17062C>T variant is absent in the population controls 
and has a single heterozygous entry in ExAC browser from the European (Non-Finnish) 
population. According to ACMG guidelines, the ADGRV1 nonsense variant should be classified 
as pathogenic as it meets the following criteria: PVS1, PM2, PM3, PP1, PP3. 
At the start of this study, we were aware of hearing loss (HL) in three sibships with 
varying audioprofiles, including two sisters who are the product of a consanguineous union. On 
the basis of the pending molecular diagnosis of Usher syndrome and the serious prognosis, the 
clinic contacted the sisters in order to request a visual examination (PID V-2 and V-3; Figure 
4.1). The sisters are now in their late third and early fourth decade. Both women report 

















Figure 4.6. Sequence electropherogram of ADGRV1 c.17062C>T (p.Arg5688Ter). Red arrow 










































































































































































































features of RP. Further testing of PID V-3 identified bone spicule pigmentation of the retina 
(Figure 4.8) and a significant reduction in peripheral visual acuity (Figure 4.9), which are 
consistent with “typical RP”. These findings prompted the clinic to counsel the women 
regarding their new diagnosis of USH2C.  
 
4.5.2 USH2A c.5777-1G>A and c.10388-2A>G Genotype/Phenotype Analyses 
The comprehensive gene panel that was offered to the clinical case of the 3-year-old 
child diagnosed with isolated hearing loss at 3 months (Family 4110; Figure 4.3) identified two 
novel USH2A splicing variants: c.5777-1G>A (Figure 4.10) and c.10388-2A>G (Figure 4.11). 
Cascade sequencing confirmed the maternal contribution as c.5777-1G>A and the paternal 
contribution as c.10388-2A>G, and verified these novel variants reside in trans (Figure 4.12). 
However, given this child’s young age and the novelty (variants of unknown significance) of 
the USH2A variants, the genetic testing results are of limited value.  
Fortuitously, the targeted USH gene panel offered to Family R0723 identified these 
same USH2A splicing variants. The proband (PID II-5) and his brother (PID II-3) are 
homozygous for UHS2A c.5777-1G>A, their nieces (PIDs III-1 and III-2) are compound 
heterozygotes (c.5777-1G>A; c.10388-2A>G; Figure 4.13). Even though the deceased brother 
(PID II-6) was not available for genetic testing, he is likely a USH2A c.5777-1G>A 
homozygote, given the strong family history of RP. Retrospective audiological data on the 
proband’s niece, PID III-1, from mid-third decade to mid-fifth decade show a stable hearing 
loss according to GenDeaf guidelines (Figure 1d; Mazzoli M, 2003). The proband (PID II-5) 
has moderate to severe hearing loss in his seventh decade, not significantly worse than his 













Figure 4.8. Retinal photograph of PID V-3 at age 27 (Family R2100). White arrows highlight 



























Figure 4.9. Central 24-2 visual threshold test of PID V-3 at age 27 (R2100) illustrating a 





















Figure 4.10. Sequence electropherogram of USH2A c.5777-1G>A, a pathogenic splicing variant 























Figure 4.11. Sequence electropherogram of USH2A c.10388-2A>G, a pathogenic splicing 
























Figure 4.12. Family R4110 Pedigree. This proband was recruited through the clinic as a 
hereditary hearing loss family. A comprehensive gene panel identified two USH2A variants of 
unknown signifance: c.5777-1G>A and c.10388-2A>G. PID II-1 is yet to present with retinitis 
pigmentosa, as she is too you to display this clinical feature of USH2A.Prior to advent of 




















Figure 4.13. Family R0723 Pedigree. This proband was recruited through the clinic as an Usher 
syndrome family through a hereditary eye study. An Usher syndrome gene panel identified two 
USH2A variants of unknown significance: c.5777-1G>A and c.10388-2A>G. Three brothers, 
PID II-3, II-5 and II-6 are homozygous for c.5777-1G>A, while PID III-1 and III-2 are 













reveals a similar clinical phenotype (data not shown). With respect to RP, the proband (PID II-
5) and his two brothers (PID II-3 and II-6) reported decreased night vision by their late 20s 
(Figure 1e); however, RP as seen in retinal photographs of the proband was not diagnosed in 
the brothers until their late 40’s (Figure 4.14). Following the diagnosis of RP in the uncles, their 
nieces who had documented hearing loss were closely monitored, and reduced visual fields 
noted at age 14 in PID III-2, indicating the first symptoms of RP. Abnormal dark adaptation 
and ERG responses were recorded in both nieces in the third decade and retinal photographs of 
PID III-2 illustrate arterial attenuation, a characteristic sign of early RP (Figure 4.14).  
 
4.3.3 USH2A c.5777-1G>A and c.10388-2A>G Experimental Validation of splicing effects  
Cascade sequencing revealed that both USH2A c.5777-1G>A and USH2A c.10388-
2A>G co-segregate with disease in families R0723 and R4110. In silico analyses using Alamut 
Visual suite of algorithms predicted that both variants cause exon skipping (MaxEnt: -100.0%, 
NNSPLICE: -100.0% and SSF: -100.0%). Using patient-derived cells, Sanger sequencing of 
cDNA confirmed that USH2A c.5777-1G>A causes the skipping of exon 29 leading to an in-
frame deletion (p. Glu1926_Ala1952del) in an affected individual (PID III-2) compared with a 
control sample (Figure 4.15). The sequencing of patient cDNA also determined that USH2A 
c.10388-2A>G activates a cryptic acceptor site 14 bps downstream of the canonical splice site 
(Figure 4.16), resulting in a premature stop codon (p.Asp3463Alafs*6). Based on cascade 
sequencing within these families and subsequent RNA analysis, USH2A c.5777-1G>A and 
c.10388-2A>G can both be classified as pathogenic variants according to the ACMG guidelines 
(PVS1, PS3, PM2, PM3, PP1, PP3) (Richards et al., 2015).  
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Figure 4.14. Family R0723 Ophthalmology Imaging. Retinal photograph of PID III-2 at age 21 
demonstrates arterial attenuation in the retina, which further deteriorates by the fifth decade as 



























































































































































































































































































































































































































































































































Two novel pathogenic variants in USH2A account for cases recruited or referred as 
isolated hearing or vision loss in two families in this study. Clinical evidence suggests that the 
two novel USH2A pathogenic variants result in congenital moderate to severe HL, and RP in 
the pre/post-pubertal period; findings similar to that of previously reported pathogenic variants 
in USH2A(Lentz & Keats, 1993). Several affected family members present as compound 
heterozygotes, suggesting that both USH2A c.5777-1G>A and c.10388-2A>G pathogenic 
variants are sufficient to cause USH2A and therefore are USH2A-specific. This finding is 
consistent with the allelic hierarchy model of USH2A alleles, which suggests that certain alleles 
are USH2A-specific and others RP-specific, and the presence of at least one RP-specific allele 
causes isolated RP with normal hearing (Lenassi et al., 2015). Given our clinical case with a 
young girl who also tested positive for both of these alleles, we are now increasing surveillance 
for visual symptoms, leading to improved management of USH.  
 Similarly, we find that two sisters with hereditary hearing loss, the product of a second 
cousin union, are homozygous for a nonsense pathogenic variant in ADGRV1 (c.17062C>T, 
p.Arg5688*). Visual examination secondary to molecular analyses confirmed typical RP (late 
third and fourth decade) in addition to hearing loss (first decade) and prompted a corrected 
USH diagnosis. This is consistent with previous reports of ADGRV1 pathogenic variants 
associated with early onset of hearing loss with delayed visual impairment (Abadie et al., 2012; 
Fuster-Garcia et al., 2018), most of which are located in the calx-β motif (Schwartz et al., 
2005), and the ADGRV1 c.17062C>T lies downstream (3’) to this calx-β motif. This variant is 
rare, and to our knowledge, has only been reported once before when it was identified in 1/31 
French non-USH2A patients (Besnard et al., 2012). In addition to causing USH2C, nonsense 
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ADGRV1 pathogenic variants have been shown to cause dominant audiogenic epilepsy 
(Nakayama et al., 2002; Skradski et al., 2001). However, the two affected sisters from R2100 
whom are homozygous for ADGRV1 c.17062C>T do not present with audiogenic epilepsy.  
Clinically, USH2 should be suspected in patients with bilateral, congenital, 
sensorineural, mild to severe hearing loss, normal vestibular function, and post-pubertal RP, 
most often in the second decade (Lentz J, December 10, 1999; Mathur & Yang, 2015). Visual 
examinations revealed a ‘typical RP’ phenotype in patients diagnosed with USH2A or USH2C 
(Schwartz et al., 2005). Likewise, from an audiological standpoint, our data is consistent with 
previous reports of a stable moderate to severe hearing loss (Abadie et al., 2012; Besnard et al., 
2012; Eandi et al., 2017; Garcia-Garcia et al., 2013). These results indicate that USH2A and 
USH2C are not readily discerned phenotypically (Schwartz et al., 2005). The USH2A, 
ADGRV1 and WHRN proteins co-localize at the stereocilia base in developing cochlear hair 
cells and together form the Ankle-link complex at the base of sensory hair cells and at the 
periciliary membrane complex of photoreceptors (Liu et al., 2007; Richardson & Petit, 2019; 
Yang et al., 2010), so it is not surprising that the USH2A and USH2C phenotypes are 
indistinguishable.  
To determine variant pathogenicity, clinical best-practice guidelines, such as ACMG 
(Richards et al., 2015) and EuroGentest (Matthijs et al., 2016) are important to follow. For the 
splicing variants, we used in silico prediction algorithms for preliminary assessment only, and 
experimentally confirmed the splicing effects using patient-derived B-cell lines. For the 
nonsense variant, we confirmed that the parents were unaffected carriers and that their affected 
children received one copy of the novel nonsense ADGRV1 c.17062C>T variant from each of 
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them, establishing that we are detecting two disease alleles in trans and confirming the 
recessive pattern for Usher syndrome. 
In a recent meta-analysis including all of the known genes causing usher syndrome, 
USH2A (50%) mutations are the most common with ADGRV1 mutations being less frequent 
(5%) in patients with both visual and hearing impairments (Jouret et al., 2019). In patients with 
seemingly isolated sensorineural deafness, 7.5% had disease-causing mutations in USH genes, 
and are therefore at high risk of developing RP. In isolated cases of ‘hearing loss’ or ‘vision 
loss’, it is important to screen both USH and RP genes, as an accurate diagnosis of Usher 
syndrome is essential for patient clinical follow-up, particularly the referral and access to the 
correct support systems. 
 
4.7 Conclusions 
Recognition of syndromic forms of both hearing and vision loss, especially Usher 
syndrome, is important given the major impact of these types of sensory losses on the 
acquisition of speech in children and quality of life for adults. In this report, USH was not 
considered in these cases until genetic testing was performed. Close collaboration between local 
clinics and molecular genetics researchers was necessary to fully categorized three novel USH 
variants as pathogenic using ACMG criteria. Accurate molecular diagnosis of patients is 
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Chapter 5: General Discussion and Conclusions 
 The overarching goal of this dissertation was to define and characterize the genetic basis 
of hereditary hearing loss in the NL genetic isolate. This thesis employs a “multi-omic” 
approach to gene discovery by combining both traditional robust methods such as linkage 
analysis and haplotyping, when large families are available, with modern NGS technologies 
and molecular tools that discern the impact of genomic variation at the RNA-level. Genetic 
isolates and founder populations have provided unprecedented opportunities in uncovering the 
genetic factors that contribute to disease. In lieu of identifying many pathogenic variants that 
have been enriched in the NL population, due to founder effects(Abdelfatah et al., 2013; 
Ahmed et al., 2004; Kopciuk et al., 2009; Merner et al., 2008; Olufemi et al., 1998; Spirio et 
al., 1999), this genetic isolate further exemplifies the importance and power of performing 
genomic studies on homogenous populations. 
 Non-syndromic, autosomal recessive, hearing loss accounts for the vast majority of 
monogenic deafness and is most commonly caused by homozygous or compound heterozygous 
variants in GJB2(Richard JH Smith, 1999 ). Until recently, many clinical molecular genetics 
laboratories only tested GJB2 during routine newborn hearing screening investigations, 
representing a significant ascertainment bias that may skew the true genetic epidemiology of 
recessive hearing loss(Snoeckx et al., 2005). Despite these biases, targeted genomic enrichment 
and NGS has accelerated the molecular diagnosis of hearing loss, with a diagnostic rate ranging 
from 10% - 84%(Shearer & Smith, 2015). Many factors may be contributing to this variable 
diagnostic rate, including platform enrichment bias that captures a specific set of know hearing 
loss genes and study participant bias that examines specific ethnicities with a known family 
history of deafness(Sloan-Heggen et al., 2016). As outlined in the general introduction, the 
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hereditary hearing loss project began with the targeted sequencing of known pathogenic 
variants in all recruited families in the study. All families who screened negative were subject 
to more comprehensive genomic investigations.  
After screening negative for known hearing loss alleles, Family R2010 underwent WES, 
which identified a pathogenic missense variant, CLDN14 c.488C>T (p.Ala163Val; DFNB29), 
in several NL families. Upon initial inspection of hearing loss inheritance in Family 2010, we 
believed that this was a dominant trait, due to the vertical transmission from the proband to her 
son. Throughout ongoing clinical recruitment during a rural outreach field trip to the Burin 
peninsula, our hearing loss reach team noted that that the audioprofile within this family was 
remarkably similar amongst the kinship, with intact hearing threshold in the lower frequencies 
that precipitously deteriorate after 500 Hz. Our clinical audiologist noted that this specific 
phenotype was present in two additional families, R2033 and R2075, who screened positive for 
CLDN14. Subsequently, the sequencing of hearing loss probands revealed a fourth CLDN14 
family, R2072, who also presented with this precipitous, pathognomonic, audioprofile. 
Although genealogical studies identified a common ancestor between families R2010, R2033, 
and R2075, haplotype analysis identified a 1.4 Mb disease haplotype across all four families, 
indicating shared ancestry between R2072 and the larger clan. This CLDN14 allele is common 
to the NL population, which explains the pseudodominant inheritance pattern that is observed 
in two of the families.  
Within ExAC browser, CLDN14 c.488C>T has 31 heterozygous submissions, with a  
global MAF of 0.02564% (Lek et al., 2016). After first being identified in Iceland(Thorleifsson 
et al., 2009), carriers for this pathogenic variant was reported in the USA(Toka et al., 2013), 
Sweden(Purcell et al., 2014), and Africa(Lek et al., 2016). Given the presence 
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CLDN14 c.488C>T in many populations, this allele should be of interest to molecular 
diagnostic laboratories around the world. Until our DFNB29 study, pathogenic variants in 
CLDN14 have been shown to cause congenital hearing loss with a phenotype that exhibits 
variable expressivity(R. Bashir et al., 2010; Z. E. Bashir et al., 2013; Wilcox et al., 2001).  
However, we have shown that pathogenic CLDN14 variants can cause non-congenital, 
prelingual hearing loss, with considerable conservation in audiogram configuration. Without 
genetic testing, children who are CLDN14-positive would not be detected at newborn hearing 
screening.  
Since the publication of Chapter 2, CLDN14 c.488C>T has been included in a targeted 
hearing loss gene panel that has identified several NL families who were CLDN14-positive, 
highlighting the urgent need for NGS technologies in the clinical setting. Not only can this 
approach expedite the molecular diagnosis of hearing loss, it can also provide appropriate 
hearing surveillance for children at-risk of developing significant delays that lead to language 
and learning deficits. Even though NGS is an effective diagnostic modality, the lack of 
extended pedigrees in the clinic presents a significant challenge during variant interpretation 
and it is recommended to use caution when the phasing of disease alleles and segregation 
analysis is unavailable(Lewis et al., 2018). Given that there are the millions of heterozygous 
variants across the human genome(Sherry et al., 2001), performing segregation analysis is 
especially relevant to autosomal dominant traits. Despite the identification of approximately 
143 hearing loss genes, approximately 1/3 of DFNA loci have evaded discovery72,76, due to the 
lack of large kinships, broad critical regions, well-described phenotype data, as well as reduced 
penetrance and the inter- and intrafamilial variability of dominant hearing phenotypes(Richard 
JH Smith, 1999 ).  
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Chapter 3 represents the most significant scientific discovery of this dissertation, the 
identification of a novel autosomal dominant gene that maps to the DFNA33 locus. The purpose 
of this study was to discern the genetic basis of hearing loss in Family R2070, a large multiplex 
kinship from the Western region of NL with apparent autosomal dominant hearing loss. Several 
genomic technologies were employed throughout this project. Previous work including 
genome-wide SNP genotyping and multipoint linkage analysis mapped the hearing loss trait in 
family R2070 to chromosome 13q34. Even though WES failed to solve this family, the 
combination of WGS and a comprehensive bioinformatics approach identified two candidate 
variants within this region. The first variant, COL4A1 c.3326-7dupT, was in close proximity to 
the exon-intron boundary; however, experimental RNA evidence demonstrates that this variant 
exerts no effect at the RNA-level. The second variant, ATP11A c.*11G>A, was predicted to 
destroy the canonical +/− 1 or 2 donor splice site and was first identified in ATP11A-203, a 
poorly supported suspect expressed sequence tag (EST). Haplotype analysis established a 3.3 
Mb critical region, which was further reduced to 769 Kb by two separate recombination events 
to the disease-associated haplotype that excluded COL4A1 as a candidate gene.  
For the most part, our current understanding of the human genome is relatively 
complete; conversely, the same cannot be said about the human transcriptome and the non-
coding DNA elements that regulate alternative splicing(Macaulay et al., 2017). An excellent 
example of this is the identification of COL11A, a gene that causes DFNA37(Booth, Askew, et 
al., 2018). However, this discovery was not trivial(Talebizadeh, 2018). In a recent commentary 
entitled Lessons learned from the DFNA37 gene discovery odyssey(Talebizadeh, 2018), Dr. 
Zohreh Talebizadeh eloquently outlined the many challenges associated with hearing loss gene 
discoveries. Upon the discovery of DFNA37 on chromosome 1p21, Dr. Talebizadeh prioritized 
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the Sanger sequencing of the complete COL11A1 cDNA sequence, due to its association with 
Marshall syndrome(Griffith et al., 1998). At the RNA level, Talebizadeh et al found a messy 
electropherogram pattern that spanned exons 4 and 5 in the DFNA37 proband, which was 
absent in unaffected family members. Yet, the sequencing of genomic DNA samples found an 
out-of-phase electropherogram within the intron 4 and exon 5 boundary in both affected and 
unaffected samples. Taken together, the cDNA sequencing results was perceived as a PCR 
artifact, resulting in the false-negative exclusion of COL11A1 as the DFNA37 gene. Twenty 
years later, a collaborative, multicentre study re-examined the DFNA37 family using NGS and 
discovered a novel pathogenic splicing variant, c.652-2A>C, which caused the skipping of exon 
5(Macaulay et al., 2017). Furthermore, an out-of-frame deletion, c.652-6_-17del, was revealed 
in both the proband and unaffected family members, which masked the c.652-2A>C allele and 
explained the out-of-phase electropherogram when this study first began. Due to the lack of 
selection pressure, introns can vary in both in length and sequence, relative to exons(Tom 
Strachan, 2010). In addition to the polymorphic nature of intronic sequences, the difficulty of 
studying DNA variation at the RNA level is further confounded by over 8 million ESTs across 
the genome(dbEST, 2019). When performing RT-PCR, several amplicons can be produced that 
represent multiple gene transcripts that are either be under- or over-represented, depending on 
the tissue or cell type in question(Nagaraj et al., 2007). In order to properly interpret these 
confusing results, more advanced molecular tools are required, such as TA-cloning. 
Alternatively, in vitro assays can also be employed in determining the role of candidate splicing 
variants, as was performed in a recent investigation of pathogenic DFNA5 missense variants 
that cause exon skipping(Booth, Azaiez, et al., 2018). These examples highlight the importance 
of knowing and understanding our assumptions during experimental design, as well as how 
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complicated gene discovery efforts can be when deciphering the intricate functional impact of 
variants at the RNA level.  
While many studies routinely use commercially available cell line to investigate splicing 
variants, we were fortunate in that we could extract RNA from patient-derived B-cell 
lymphocytes. RNA analyses revealed that exon 2 from ATP11A-203 was in fact marking a 
nascent exon that was missing from three alternatively spliced transcripts, ATP11A-201, 
ATP11A-212 and ATP11A-202. Accounting for the addition of this exon, the c.*11 variant in 
exon 2 of ATP11A-203 is located at the same position in ATP11A-201 but positioned at c.*113 
in ATP11A-202/212. As demonstrated by RT-PCR, cloning, and sequencing, this variant 
activates a cryptic splice site that inserts 153 bp into the 3’ UTR of ATP11A-201, ATP11A-212 
and ATP11A-202. P4-ATPases play a critical role in maintaining phospholipid asymmetry in 
eukaryotic membranes(Paulusma & Elferink, 2010). Specifically, ATP11A and its paralog 
ATP11C are the most abundant P4-ATPases in mammalian cells, ensuring that PS in enriched 
and devoid in cytosolic and extracellular leaflets of plasma membrane, respectively(Segawa et 
al., 2016; Segawa et al., 2014). Under normal physiology, PS is enriched in the extracellular 
leaflet of damaged or weakened cells, marking them for phagocytosis and the completion of 
apoptosis(Paulusma & Elferink, 2010). Given that ATP11A is highly expressed in sensory hair 
cells and spiral ganglion neurons(Shen et al., 2015), this dissertation proposes that this 
pathogenic ATP11A variant causes haploinsufficiency, leading to aberrant phagocytosis of 
healthy cells that are required normal auditory function. Together, we are confident that we 
have identified that genetic cause of hearing loss in this large NL family; although, functional 
luciferase assays are required to confirm this hypothesis.  
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 To say the least, the discovery of ATP11A was quite challenging. Despite the many 
obstacles throughout this project, many important lessons were learnt along the way that 
emphasizes the importance of understanding the fundamental assumptions that are made during 
NGS variant filtration and the strengths and limitations of WES and WGS capture platforms. 
Upon the discovery of ATP11A using a PCR-free WGS capture platform, Geoff Woodland and 
I retrospectively reviewed how well this gene was covered by Ion Torrent WES. According to 
Ion Torrent WES metrics, the entire ATP11A gene was sufficiently covered to meet our variant 
filtration criteria. However, the Ion Torrent WES sequencing platform does not include probes 
that captures our ATP11A variant at chr13: 113,534,962. Provided that the human transcriptome 
is comprised of over of 200,000 protein coding transcripts(Hu et al., 2015) and the Ion Torrent 
Hi-Q WES platform was designed to sequence 97.5% of all exons within the Consensus CDS 
(CCDS) project(Damiati et al., 2016), it is unlikely that poorly supported transcripts (i.e. 
ATP11A-203) that are found within other reference databases are captured. Even though the 
RefSeq Gene, Ensembl, and UCSC reference databases display a considerable amount of 
discordance with respect to the number of genes, transcripts, and exons, it is important to note 
that no database is perfect, which may result in inaccurate variant annotations(Zhao & Zhang, 
2015). According to Wu et al(Wu et al., 2013), it is behoving to employ a more reproducible 
and robust reference genome when performing research at the clinical level, while more 
complex reference genomes are more appropriate for exploratory research, such as gene 
discovery.  
 The final research chapter of the thesis was extremely enlightening with respect to the 
clinical features of syndromic hearing loss (i.e. USH) and how they can present when least 
expected. USH is the leading cause of combined hearing and vision loss, which is most 
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commonly caused by pathogenic variants in the USH2 subtype; namely, USH2A, ADGRV1, and 
WHRN (MIM: 607928), (Lentz J, December 10, 1999). Family R2100 was first recruited to our 
study with apparent dominant non-syndromic hearing loss. However WES revealed a 
deleterious nonsense variant, ADGRV1 c.17062C>T (p.Arg5688Ter) in two affected sisters. 
Upon review of the USH literature, we were concerned about visual impairment, even though 
no signs or symptoms were known at ascertainment. Subsequent follow-up with these siblings 
identified “typical RP” findings, prompting an USH2C diagnosis. Concurrently, two likely 
pathogenic USH2A splicing variants, c.5777-1G>A and c.10388-2A>G, were identified by the 
clinic in a 3-year old girl who was GJB2-negative. Through Dr. Green’s hereditary eye study, 
these same USH2A variants were identified in Family R0723, an apparent non-syndromic RP 
kinship; however, it was noted that some of family members were fitted with hearing aids, 
which was followed by an USH2A diagnosis. RNA analyses confirmed that these USH2A 
variants cause cryptic splicing. Despite exon skipping predictions, in silico, only c.5777-1G>A 
was experimentally validated, while c.10388-2A>G creates a frameshift by activating a cryptic 
acceptor site 14 bp downstream. While these variants can be reclassified as pathogenic variants, 
it’s important to appreciate that in silico predictions lack the ability to predict the precise 
splicing effect, and these variants could have easily caused a more tolerable in-frame 
INDEL(Ernst et al., 2018). Throughout this study, I was perplexed as to why USH went 
undetected in these families until the identification of these variants. This story highlights one 
of the major limitations in studying genetic isolates, the lack of accessible health care in remote 
communities(Green, Personal communication: Discussion on health care access in NL - 
October 4 2018). Without a complete family history, the affection status of members may be 
erroneously annotated on pedigrees and misguide molecular studies. Collectively, this research 
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chapter revealed several variants that can be translated into the clinic to diagnose, treat and 
manage patients at-risk of developing USH. 
For those patients with USH2, pathogenic variants in USH2A account for an 
estimated 75% – 90% of cases(Aller et al., 2006; Baux et al., 2007; Dreyer et al., 2008), 
while ADGRV1 is more rare at 3% – 6%(Besnard et al., 2012; Ebermann et al., 2009; 
Weston et al., 2004). Previously, the prevalence of USH was once thought to be 1 in 
26,000(Boughman et al., 1983). However, more recent estimate of 1 in 6,000  was found in the 
European population(Kimberling et al., 2010); although, the frequency of USH and the 
underlying causative genetic defect is dependent on ethnicity(Khalaileh et al., 2018). For 
example, USH2A variant, c.2299delG, is the most common allele in the European population, 
while it is present in isolated cases within the South American, African and Asian 
populations(Dreyer et al., 2001). Similarly, pathogenic variants in ADGRV1 appear to be more 
frequent in the Europe(Besnard et al., 2012), given that 2018 marks the first reports of 
USH2C in the Israeli and Palestinian populations(Khalaileh et al., 2018). While we observe 
much higher allele frequencies within the European population, it is important to note that 
the vast majority of participants that are enrolled in large-scale sequencing projects are of 
European descent(Popejoy & Fullerton, 2016). This may skew our understanding of the 
prevalence of certain diseases, such as USH, and allele frequencies amongst minority 
groups. 
 The genes of the USH2 subtype, USH2A, ADGRV1 and WHRN encode for the Usherin, 
VLGR1, and Whirlin proteins, respectively. Given that these proteins interact with one another 
to form a multimeric ankle-link complex at the base of sensory hair cells and at the periciliary 
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membrane complex of photoreceptors(Liu et al., 2007; Richardson & Petit, 2019; Yang et al., 
2010), it is no surprise that they cause an indistinguishable phenotype. The Usherin and 
VLGR1 proteins are very similar in that they possess very large extracellular domains and 
relatively short C-terminal cytoplasmic regions that carry PDZ domain-binding motifs(Adato et 
al., 2005; Michalski et al., 2007). In the cytoplasm of sensory hair cells and photoreceptors, 
Whirlin and PDZD7, a protein encoded by PDZD7, which is a modifier of USH2C (MIM: 
602851) (Ebermann et al., 2010) and also causes DFNB57 (MIM: 618003)(Booth et al., 2015), 
form a heterodimer scaffolding complex; in turn, this heterodimer interacts with the PDZ 
domains of Usherin and VLGR1, recruiting them to the ankle link complex(Chen et al., 2014). 
Together, this complex is believed to participate in linking the base of sensory hair cells and at 
the periciliary membrane complex of photoreceptors to various extracellular matrix proteins, as 
well as cell adhesion proteins in order to provide structural support(Yang et al., 2012) 
 In conclusion, these projects emphasize the usefulness of applying a comprehensive 
“multi-omic” approach while investigating hereditary hearing loss in large extended families 
from genetic isolates, such as NL. In addition to combining NGS technologies, such as WES 
and WGS, with the power of linkage analysis, I also employed tools to study genetic variants at 
the RNA-level, which solved seven families and discovered a novel dominant hearing loss 
gene. Together, these studies have significantly contributed to the hereditary hearing loss field 
and are of great importance to the clinical diagnosis, management and treatment of these 
families, including the enrolment into gene therapy and small molecule trails. By understanding 
the genetic basis of hearing loss in affected families, innovative treatments can be offered that 
improve quality of life and contribute to the era of precision medicine.  
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5.1 Future Directions 
 While the CLDN14, ADGRV1 and USH2A variants that have been identified in this 
thesis sufficiently fulfill the pathogenic ACMG criteria, our pathogenic ATP11A variant 
requires functional analyses to determine the molecular mechanism of disease. Given that our 
ATP11A variant resides within the 3 ‘UTR, we hypothesize that aberrant miRNA silencing of 
the mRNA is the most likely molecular disease mechanism. In order to answer this question, a 
dual luciferase assay would be required to determine if ATP11A mRNA destabilization was 
occurring at post-transcriptional level. In short, both the wild-type and mutant ATP11A 3’UTRs 
would be cloned into the pmirGLO Dual-Luciferase miRNA Target Expression Vector 
(Promega Cat.# E1330), and transfected into a mammalian auditory sensory hair cell line (HEI-
OC1 cells). Preceding this, quantitative PCR for known auditory system miRNAs(Rudnicki et 
al., 2014) would be performed to determine the suitability of using this HEI-OC1 cell line. 
Assuming that our ATP11A variant causes dysregulated gene expression, our next steps would 
be to knockout ATP11A in HEI-OC1 cells using CRISPR-Cas9, followed by 
immunofluorescence and immunoblot assays. We would perform immunofluorescence on 
mutant and wild-type ATP11A in HEI-OC1 cells with Anti-Phosphatidylserine antibodies to 
determine the spatial localization of this phagocytic signal. Subsequently, immunoblotting for 
cleaved caspase-3 would indicate whether the loss of ATP11A induces apoptosis. In being 
certain of these results, TUNEL assays comparing wild-type and ATP11A null HEI-OC1 cells 
would confirm these findings. Finally, investigating ATP11A, in vivo, would be paramount in 
establishing this genes role in hearing loss. Luckily, a atp11a-null mouse has already been 
established, which is cryopreserved at The Jackson Laboratories in Bar Harbour, Maine, USA. 
Assessing the role of ATP11A in hearing loss would involve measuring auditory brainstem 
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responses periodically throughout life; specifically, at birth, one month, three months, six 
months. Since hearing loss due to ATP11A can present as an adult, it is important to assess 
auditory brainstem responses outside the neonatal period. Thereafter, mice would be sacrificed, 
where components of the auditory system (including the cochlea and spiral ganglion tissues) 
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Appendix 
Appendix A – ACMG Standards and guidelines for the interpretation of sequence 
variants(Richards et al., 2015). Provided here are the 28 criteria for the annotation of sequence 
variants. All variants identified in this thesis are bolded and in brackets after the criteria 
statement.  
 
Evidence for variant pathogenicity:  
Very Strong 
1) PVS1: null variant (nonsense, frameshift, canonical ±1 or 2 splice sites, initiation codon, 
single or multiexon deletion) in a gene where LOF is a known mechanism of disease 
(ADGRV1, USH2A)  
Strong 
2) PS1: Same amino acid change as a previously established pathogenic variant regardless 
of nucleotide change  
3) PS2: De novo (both maternity and paternity confirmed) in a patient with the disease and 
no family history  
4) PS3: Well-established in vitro or in vivo functional studies supportive of a damaging 
effect on the gene or gene product (USH2A) 
5) PS4: The prevalence of the variant in affected individuals is significantly increased 
compared with the prevalence in controls (CLDN14; USH2A; ADGRV1; ATP11A) 
 
Moderate 
6) PM1: Located in a mutational hot spot and/or critical and well-established functional 
domain (e.g., active site of an enzyme) without benign variation (CLDN14) 
7) PM2: Absent from controls (or at extremely low frequency if recessive) in Exome 
Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium 
(CLDN14; ADGRV1; USH2A; ATP11A) 
8) PM3: For recessive disorders, detected in trans with a pathogenic variant (CLDN14 ; 
ADGRV1) 
9) PM4: Protein length changes as a result of in-frame deletions/insertions in a nonrepeat 
region or stop-loss variants  
10) PM5: Novel missense change at an amino acid residue where a different missense 
change determined to be pathogenic has been seen before  
11) PM6: Assumed de novo, but without confirmation of paternity and maternity   
 
Supporting 
12 PP1: Cosegregation with disease in multiple affected family members in a gene 
definitively known to cause the disease (CLDN14 ; ADGRV1; USH2A; ATP11A) 
13 PP2: Missense variant in a gene that has a low rate of benign missense variation and in 
which missense variants are a common mechanism of disease (CLDN14) 
14) PP3: Multiple lines of computational evidence support a deleterious effect on the gene 
or gene product (conservation, evolutionary, splicing impact, etc.) (CLDN14 ; 
ADGRV1; USH2A; ATP11A) 
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15) PP4: Patient’s phenotype or family history is highly specific for a disease with a single 
genetic etiology (CLDN14; ADGRV1; USH2A; ATP11A) 
16) PP5: Reputable source recently reports variant as pathogenic, but the evidence is not 
available to the laboratory to perform an independent evaluation 
 
Criteria for the annotation of benign variants: 
Stand Alone 
17) BA1: Allele frequency is >5% in Exome Sequencing Project, 1000 Genomes Project, or 
Exome Aggregation Consortium  
Strong 
18) BS1: Allele frequency is greater than expected for disorder  
19) BS2: Observed in a healthy adult individual for a recessive (homozygous), dominant 
(heterozygous), or X-linked (hemizygous) disorder, with full penetrance expected at an 
early age 
20) BS3: Well-established in vitro or in vivo functional studies show no damaging effect on 
protein function or splicing BS4 Lack of segregation in affected members of a family  
21) BS4: Lack of segregation in affected members of a family  
 
Supporting  
22) BP1: Missense variant in a gene for which primarily truncating variants are known to 
cause disease  
23) BP2: Observed in trans with a pathogenic variant for a fully penetrant dominant 
gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern  
24) BP3: In-frame deletions/insertions in a repetitive region without a known function  
25) BP4: Multiple lines of computational evidence suggest no impact on gene or gene 
product (conservation, evolutionary, splicing impact, etc.)  
26) BP5: Variant found in a case with an alternate molecular basis for disease  
27) BP6: Reputable source recently reports variant as benign, but the evidence is not 
available to the laboratory to perform an independent evaluation  
28) BP7: A synonymous (silent) variant for which splicing prediction algorithms predict no 
impact to the splice consensus sequence nor the creation of a new splice site AND the 
















Appendix B – Loci and Genes of Hereditary Hearing Loss and its Syndromes 
Non-syndromic Sensorineural Hearing Loss 
 
Autosomal Dominant Sensorineural Hearing Loss Loci and Genes 
Locus (OMIM) Location Gene (OMIM) 
DFNA1 5q31 DIAPH1 
DFNA2A 1p34 KCNQ4 
DFNA2B 1p35.1 GJB3 
DFNA2C  IFNLR1 
DFNA3A 13q11-q12 GJB2 
DFNA3B 13q12 GJB6 
DFNA4A 19q13 MYH14 
DFNA4B 19q13.32 CEACAM16 
DFNA5 7p15 GSDME  
DFNA6 4p16.3 WFS1 
DFNA7 1q21-q23 LMX1A 
DFNA8 see DFNA12  
DFNA9 14q12-q13 COCH 
DFNA10 6q22-q23 EYA4 
DFNA11 11q12.3-q21 MYO7A 
DFNA12 11q22-24  TECTA 
DFNA13 6p21 COL11A2 
DFNA14 see DFNA6  
DFNA15 5q31 POU4F3 
DFNA16 2q24 unknown 
DFNA17 22q MYH9 
DFNA18 3q22 unknown 
DFNA19 10 (pericentric) unknown 
DFNA20 17q25 ACTG1 
DFNA21 6p21 unknown 
DFNA22 6q13 MYO6 
DFNA23 14q21-q22 SIX1 
DFNA24 4q unknown 
DFNA25 12q21-24 SLC17A8 
DFNA26 see DFNA20  
DFNA27 4q12 REST 
DFNA28 8q22 GRHL2  
DFNA30 15q25-26 unknown 
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DFNA31 6p21.3 unknown 
DFNA32 11p15 unknown 
DFNA33 13q34-qter unknown 
DFNA34 1q44 NLRP3 
DFNA36 9q13-q21 TMC1 
DFNA37 1p21 COL11A1 
DFNA38 see DFNA6  
DFNA39  4q21.3 DSPP 
DFNA40 16p12.2 CRYM 
DFNA41 12q24-qter P2RX2 
DFNA42 5q31.1-q32 unknown 
DFNA43 2p12 unknown   
DFNA44 3q28-29 CCDC50 
DFNA47 9p21-22 unknown 
DFNA48 12q13-q14 MYO1A 
DFNA49 1q21-q23 unknown 
DFNA50 7q32.2 MIRN96 
DFNA51 9q21 TJP2 
DFNA52 4q28 unknown   
DFNA53 14q11.2-q12 unknown 
DFNA54 5q31 unknown 
DFNA56 9q31.3-q34.3 TNC 
DFNA57 19p13.2 unknown 
DFNA58 2p12-p21 unknown 
DFNA59 11p14.2-q12.3 unknown 
DFNA60 2q21.3-q24.1 unknown 
DFNA64 12q24.31-q24.32 SMAC/DIABLO 
DFNA65 16p13.3 TBC1D24 
DFNA66 6q15-21 CD164 
DFNA67 20q13.33 OSBPL2 
DFNA68 15q25.2 HOMER2 
DFNA69 12q21.32-q23.1 KITLG 
DFNA70 3q21.3 MCM2 
DFNA73 12q21.31 PTPRQ 






Autosomal Recessive Sensorineural Hearing Loss Loci and Genes 
Locus (OMIM) Location Gene (OMIM) 
DFNB1A 13q12 GJB2 
DFNB1B 13q12 GJB6 
DFNB2 11q13.5 MYO7A 
DFNB3 17p11.2 MYO15A 
DFNB4 7q31 SLC26A4 
DFNB5 14q12 unknown 
DFNB6 3p14-p21 TMIE 
DFNB7/11 9q13-q21 TMC1 
DFNB8/10 21q22 TMPRSS3 
DFNB9  2p22-p23 OTOF 
DFNB10 see DFNB8  
DFNB11 see DFNB7  
DFNB12 10q21-q22 CDH23 
DFNB13 7q34-36 unknown 
DFNB14 7q31 unknown 
DFNB15/72/95 3q21-q25 GIPC3  19p13 
DFNB16 15q21-q22 STRC 
DFNB17 7q31 unknown 
DFNB18 11p14-15.1 USH1C 
DFNB18B 11p15.1 OTOG 
DFNB19 18p11 unknown 
DFNB20 11q25-qter unknown 
DFNB21 11q TECTA 
DFNB22 16p12.2 OTOA 
DFNB23 10p11.2-q21 PCDH15 
DFNB24 11q23 RDX 
DFNB25 4p13 GRXCR1 
DFNB26  4q31 GAB1 
DFNB27 2q23-q31 unknown 
DFNB28 22q13 TRIOBP 
DFNB29 21q22 CLDN14 
DFNB30 10p11.1 MYO3A 
DFNB31 9q32-q34 WHRN 
DFNB32/105 1p13.3-22.1 CDC14A 
DFNB33 9q34.3 unknown 
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DFNB35 14q24.1-24.3 ESRRB 
DFNB36 1p36.3 ESPN 
DFNB37 6q13 MYO6 
DFNB38 6q26-q27 unknown 
DFNB39 7q21.1 HGF 
DFNB40 22q unknown 
DFNB42 3q13.31-q22.3 ILDR1 
DFNB44 7p14.1-q11.22 ADCY1 
DFNB45 1q43-q44 unknown 
DFNB46 18p11.32-p11.31 unknown 
DFNB47 2p25.1-p24.3 unknown 
DFNB48 15q23-q25.1 CIB2 
DFNB49 5q12.3-q14.1. MARVELD2/BDP1 
DFNB51 11p13-p12 unknown 
DFNB53 6p21.3 COL11A2 
DFNB55 4q12-q13.2 unknown 
DFNB59 2q31.1-q31.3 PJVK 
DFNB60 5q23.2-q31.1 SLC22A4 
DFNB61 7q22.1 SLC26A5 
DFNB62 12p13.2-p11.23 unknown 
DFNB63 11q13.2-q13.4 LRTOMT / COMT2 
DFNB65 20q13.2-q13.32 unknown 
DFNB66 6p21.2-22.3 DCDC2 
DFNB66/67 6p21.31 LHFPL5 
DFNB68 19p13.2 S1PR2 
DFNB71 8p22-21.3 unknown 
DFNB72 see DFNB15  
DFNB73 1p32.3 BSND 
DFNB74 12q14.2-q15 MSRB3 
DFNB76 19q13.12 SYNE4 
DFNB77 18q12-q21 LOXHD1 
DFNB79 9q34.3 TPRN 
DFNB80 2p16.1-p21 unknown 
DFNB81 19p unknown 
DFNB82 1p13.1 (see note 4) 
DFNB83 see DFNA47  
DFNB84 12q21.2 PTPRQ / OTOGL 
DFNB85 17p12-q11.2 unknown 
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DFNB86 16p13.3 TBC1D24 
DFNB88 2p12-p11.2 ELMOD3 
DFNB89 16q21-q23.2 KARS 
DFNB90 7p22.1-p15.3 unknown 
DFNB91 6p25 SERPINB6 
DFNB93 11q12.3-11q13.2 CABP2 
DFNB94  NARS2 
DFNB95 see DFNB15  
DFNB96 1p36.31-p36.13 unknown 
DFNB97 7q31.2-q31.31 MET 
DFNB98 21q22.3-qter TSPEAR 
DFNB99 17q12 TMEM132E 
DFNB100 5q13.2-q23.2 PPIP5K2 
DFNB101 5q32 GRXCR2 
DFNB102 12p12.3 EPS8 
DFNB103 6p21.1 CLIC5 
DFNB104 6p22.3 FAM65B 
DFNB105 see DFNB32  
DFNB106 11p15.5 EPS8L2 
DFNB108 1p31.3 ROR1 
   
X-linked Sensorineural Hearing Loss Loci and Genes 
Locus (OMIM) Location Gene (OMIM) 
DFNX1 Xq22 PRPS1 
DFNX2 Xq21.1 POU3F4 
DFNX3 Xp21.2 unknown 
DFNX4 Xp22 SMPX 
DFNX5 Xq26.1 AIFM1 















Gene (OMIM) Genomic Location Inheritance 
COL4A3 2q36.3 Autosomal Recessive 
COL4A4 2q36.3 Autosomal Recessive 
COL4A5 Xq22.3 X-linked Recessive 
   
CHARGE Syndrome 
Gene (OMIM) Genomic Location Inheritance 
SEMA3E 7q21.11 Autosomal Dominant 
CHD7 8q12.2 Autosomal Dominant 
   
   
Pendred Syndrome 
Gene (OMIM) Genomic Location Inheritance 
SLC26A4 7q22.3 Autosomal Recessive 
FOXI1 5q35.1 Autosomal Recessive 
KCNJ10 1q23.2 Autosomal Recessive 
 
Branchio-Oto-Renal Syndrome 
Locus Gene (OMIM) Genomic Location Inheritance 
BOR1 EYA1 8q13.3 Autosomal Dominant 
BOR2 SIX5 19q13.32 Autosomal Dominant 
 Unknown 1q31 Autosomal Dominant 
BOR3 SIX1 14q23.1 Autosomal Dominant 
    
Jervell & Lange-Nielsen Syndrome 
Locus Gene (OMIM) Genomic Location Inheritance 
JLNS1 KNCQ1 11p15.5-15.4 Autosomal Recessive 
JLNS2 KCNE1 21q22.12 Autosomal Recessive 
    
Norrie Disease    
Locus Gene (OMIM) Genomic Location Inheritance 
NDP1 NDP Xp11.3 X-linked Recessive 
 
 
     
Perrault Syndrome 
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Locus Gene (OMIM) Genomic Location Inheritance 
PRLTS1 HSD17B4 5q23.1 Autosomal Recessive 
PRLTS2 HARS2 5q31.3 Autosomal Recessive 
PRLTS3/DFNB81 CLPP* 19p13.3 Autosomal Recessive 
PRLTS4 LARS2 3p21.31 Autosomal Recessive 
PRLTS5 TWNK 10q24.21 Autosomal Recessive 
PRLTS6 ERAL1 17q11.2 Autosomal Recessive 
    
Stickler Syndrome 
Locus Gene (OMIM) Genomic Location Inheritance 
STL1 COL2A1 12q13.11 Autosomal Dominant 
STL2 COL11A1 1p21 Autosomal Dominant 
STL3 COL11A2 6p21.32 Autosomal Recessive 
STL4 COL9A1 6q13 Autosomal Recessive 
STL5 COL9A2 1p34.2 Autosomal Recessive 
    
Treacher Collins Syndrome 
Locus Gene (OMIM) Genomic Location Inheritance 
TCOF1 TCOF1 5q32-q33.1 Autosomal Dominant 
TCOF2 POLR1D 13q12.2 Autosomal Dominant 
TCOF3 POLR1C 6p21.1 Autosomal Recessive 
 
 
Usher Syndrome  
Type Locus Gene (OMIM) Genomic Location Inheritance 
Usher 1 USH1A - 14q32 Autosomal Recessive 
Usher 1 USH1B MYO7A 11q13.5 Autosomal Recessive 
Usher 1 USH1C USH1C 11p15.1 Autosomal Recessive 
Usher 1 USH1D CDH23 10q22.1 Autosomal Recessive 
Usher 1 USH1E - 21q21 Autosomal Recessive 
Usher 1 USH1F PCDH15 10q21.1 Autosomal Recessive 
Usher 1 USH1G SANS/USH1G 17q25.1 Autosomal Recessive 
Usher 1 USH1H - 15q22-23 Autosomal Recessive 
Usher 1 USH1J - 15q25.1 Autosomal Recessive 
Usher 1 USH1K - 10p11.21-q21.1 Autosomal Recessive 
Usher 2 USH2A USH2A 1q41 Autosomal Recessive 
Usher 2 USH2B - 3p23-24.2 Autosomal Recessive 
Usher 2 USH2C ADGRV1 5q14.3 Autosomal Recessive 
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Usher 2 USH2D WHRN 9q32 Autosomal Recessive 
Usher 3 USH3A CLRN1 3q25.1 Autosomal Recessive 
Usher 3 USH3B HARS 5q31.1   
     
Waardenburg Syndrome    
Type Locus Gene (OMIM) Genomic Location Inheritance 
Type I WS1 PAX3 2q36.1 Autosomal Dominant 
Type II WS2A MITF 3p13 Autosomal Dominant 
Type II WS2B - 1p21-p13.3 Autosomal Dominant 
Type II WS2C - 8p23 Autosomal Dominant 
Type II WS2D SNAI2 8q11 Autosomal Recessive 
Type II WS2E SOX10 22q13.1 Autosomal Dominant 
Type III WS3 PAX3 2q36.1 Autosomal Recessive 
Type IV WS4A EDNRB 13q22.3 Autosomal Recessive 
Type IV WS4B EDN3 20q13.32 Autosomal Recessive 




Appendix C – Recurrent Hearing Loss Variants in Newfoundland before this dissertation. 
Screening for these known pathogenic hearing loss variants was performed by Mrs. Jessica 
Squires. 
 
Gene Accession No. Variant DFN Locus Locus (Cyto) 
TMPRSS3 NM_024022 c.207delC DFNB8/10 21q22 
  c.268 G>C   
  c.782+3delGAG   
  c.757 A>G   
  c.612-2insTA   
WFS1 NM_006005.3 c.2146 G>A DFNA6/14/38 4p16.3 
  c.1832 A>G   
PCDH15 NM_033056 c.1583 T>A DFNB23 10p11.2-q21 
  c.1590 + 20 A>G   
KCNQ4 NM_004700 c.806delCCT DFNA2A 1p34 





















GJB6 NM_006783 delD1351830 DFNA3B 13q12   
delD1351854  
 
GJB3 NM_024009.2 c.109 G>A DFNA2B 1p35.1 
SMPX NM_014332.2  c.99delC DFNX4 Xp22 
COCH NM_004086.2 c.151 C>T DFNA9 14q12-q13 
TECTA NM_005422 c.26557 A>G DFNB21 11q 





Appendix D – Optimized TA-cloning procedure for the Young laboratory 
 
General Notes: 
- Make sure that you use PCR products coming from a reaction a general taq polymerase. 
High fidelity taq polymerases generate PCR amplicons that have blunt ends. Since this 
is referred to as “TA cloning”, the TOPO reaction relies on the presence of “A 
overhangs” on the amplicon that are complementary to “T overhangs” on the TOPO 
vector. 
- Before Starting the TOPO cloning procedure  
o Make sure to take out the SOC cell media out of the fridge and allow it to come 
to room temperature. 
o Turn on the water bath and set it to 42OC 
- Use filter tips 
- Start preheating your agar plates at 37OC 
- Turn on the shaker and allow it to warm up to 37OC 
- Acceptable Nanodrop values after purification: 
o 260/280: >1.7 
o 260/230: >1.7 
- The amount of template you input into the TOPO reaction greatly influences the ligation 
efficiency of your PCR amplicon into the vector. The reaction requires a 10:1 ratio of 
TOPO:Purified PCR Product. The TOPO vector is 4kb in size. Therefore, if you’re 
working with a 400bp amplicon, you should be use 1 ng of template (4000bp:400bp = 
10:1). If you’re using an 800bp PCR product, you would use 0.5ng of template 
(4000bp:800bp = 5:1). If you over template the TOPO reaction, it will actually inhibit 
the topoisomerase that is attached to the vector. Inhibition of the TOPO reaction occurs 
in cases of extreme over templating. The TOPO vector tolerates slight over templating 
and I usually use 2ng of template as a starting point. After quantifying my purified PCR 
product, I dilute my sample to 2ng/ul and input 1ul of this into the TOPO Master Mix. If 




1) Combine the following reaction 
TOPO Master Mix 
Reagent Volume (uL) 
Purified PCR product 1 
Salt Solution 1 
Water 3 
TOPO Vector 1 
Total 6 
 
2) Incubate the reaction for 5-30 minutes at room temperature. The incubation period is at 
the discretion of the user. I find that I get the best results with a 15 minute incubation. 
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3) Add 2 uL of the TOPO reaction to One Shot TOP10 Chemically Competent Cells. Do 
not mix by pipetting.  
 
- Note: One Shot TOP10 Chemically Competent Cells are suspended in DMSO and are 
nutrient deprived, making them extremely unstable at this point. Make sure to minimize 
the time spent on ice before the transformation step. Avoid vigorous shaking or 
pipetting, until SOC media is added to the cells later on in the protocol. I usually allow 
them to sit on ice for 5 minutes. Therefore, after 10 minutes have gone by in the TOPO 
reaction, I bring the competent cells out of the -80 and put them on ice. 
 
4) Incubate on ice for 20 minutes 
5) Heat-shock cell for 30 second at 42OC without shaking.  
Note: make sure the water bath is already at 42OC before beginning this procedure.  
6) Immediately transfer the tubes to ice. 
7) Add 250 uL of room temperature SOC media. 
8) Shake the tube horizontally at 200 RPM at 37OC for 1 hour. 
9) Spin the cells down by centrifuging at 3000 RPM for 3 minutes. 
10) At this point there is approximately 300 uL in each tube. Aspirate 200 uL, leaving 
100uL behind.  
11) Resuspend cells by gently pipetting to mix. Make sure there are no cell clumps left in 
the cell suspension.  
12) Spread 50 uL of cells to 2 separate onto pre-warmed selective agar plates (ampicillin or 
kanamycin) and incubate at 37OC overnight.  
- Note: Ideally, you should not allow the overnight incubation to exceed 16 hours.  























































Appendix G – Whole exome sequencing identified 7 common variants (<10% MAF) identified 



































































































































































Appendix I – Family R2070 Audioprofiling.  
Each family member has a figure indicating their position on the pedigree, followed by their 











































































































































































































































































































































































































































































































































































































































Appendix J–Audioprofiling Report 
 
OVERVIEW 
Age of onset:  
• This is probably the most difficult area to understand in this family. The earliest 
audiograms on file for most family member already exhibit advanced stages of hearing 
loss.  
• PID V-6 and PID V-8 (NO DNA) present very similar when comparing their diagnostic 
audiogram. The only difference is that PID V-8 presents with a milder phenotype at age 
3, compared to a more advanced stage in PID-V-6 at age 1. The configuration of the 
audiogram is virtually identical.  
• PID V-4 presents with low frequency hearing loss at 6 years of age. 
Severity:  
• There appears to be differences in hearing loss severity within the family.  
o In the sixth decade, PID IV-4 presents with good hearing thresholds in the lower 
frequencies, relative to other family members. This trend is also similar in PID 
V-5. Again, this is hard to ascertain due to the lack of early audiological data. 
o In addition, a milder type of hearing loss is present in PID V-10 and PID V-12. 
These women have a similar audiogram configuration, when compared to the 
right ear of their married-in consanguineous aunt. 
Type of loss: 
Sloping losses: 
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• These family members are the only ones that have enough longitudinal data to form an 
opinion on. This is just my interpretation.  
o PID IV-4, PID IV-6, PID V-5, PID IV-7, PID IV-9, PID V-9, PID V-12, PID V-
10, PID V-8 
Low frequency losses: 
o PID V-4 
Mid frequency losses: 
o ID V-8 (NO DNA): starts off with normal hearing thresholds at 0.25 and 0.50 
kHz, with mild hearing loss at 1 kHz. The 3, 4, and 6 kHz thresholds come back 
into the normal range, but deteriorate into the moderate range at 8kHz. Not 
100% if this would be classified as a mid frequency loss, but the audiogram 
configuration does not seem to fit the overall picture of what is going on in the 
other family members. 
Flat losses 
• PID V-5 – similar to PID V-8  with a dip at 1 kHz frequency and more significant 
deterioration at the higher frequencies. Not 100% if this would be classified as a flat 
loss, but the audiogram configuration does not seem to fit the overall picture of what is 
going on in the other family members. 
Symmetry: 
• These family members had differences between their right and left ears. Unsure if this is 
clinically relevant.  
o PID V-5, PID IV-12, PID IV-14, PID IV-11, PID IV-7  
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Future Ascertainment:  
• On the left side of the pedigree, there are two men with apparent hearing loss. I think it 
would be beneficial to determine their clinical and genetic status.  
• PID V-4 has an affected daughter. She would provide a lot of insight with regards to 
understanding the genetic etiology of hearing loss in this family. Consenting her 
daughter is of particular importance because PID V-4 is actually the family member that 
presents with low frequency hearing loss.  
• All family members that have no DNA, but have audiological data would be nice to 
have, especially PID V-6 as they are unaffected. 
DESCRIPTION OF AUDIOLOGICAL DATA 
PID III-1 
• Onset can’t be determined, as we only have a single audiogram on file. At 76 years of 
age, subject (male) has profound, flat hearing loss on all frequencies.  
PID IV-1 
• Subject (female) has normal hearing thresholds at 36 years of age.  
PIC IV-2 
• Subject (female) has normal hearing thresholds at 55 years of age.  
PID IV-4  
• Exact onset can’t be determined. However, we do have several audiograms on file from 
the 4th, 5th and 6th decade.   
• Subject (female) has a mild, sloping to profound loss in the 4th decade. By the 6th 
decade, the lower frequencies exhibit further deterioration in the right ear, as she has a 
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moderate sloping to profound hearing loss. The left ear actually has normal hearing 
thresholds sloping to profound in the 4th decade and progresses to a mild sloping to 
profound configuration by the 6th decade.  
PID V-1 
• Subject (male) has normal hearing thresholds at 24 years of age.  
PID VI-6 
• Exact onset can’t be determined. However, we do have several audiograms on file from 
the 4th, 5th and 6th decade.   
• Subject (female) has a mild, sloping to profound loss in the 3rd and 4th decade, 
progressing to a moderate, sloping to profound loss in the 5th and 6th decade. 
PID IV-5 
• Subject (female) has normal hearing with a noise notch affecting the 4 & 6 kHz 
frequencies in the right ear and the 4, 6 and 8 kHz frequencies in the left ear.   
PID V-4 
• Onset can’t be determined, but we have audio data from the first decade. Subject 
presents with moderate, sloping to normal low frequency hearing loss at the age of 6. 
Further deterioration at all frequencies is seen at age 9, leading a profound loss at all 
frequencies in the third decade.  
PID V-5 
• Onset can’t be determined, but we have audio data from the first decade. Subject 
presents with moderate, sloping to normal low frequency hearing loss at the age of 6. 
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Further deterioration at all frequencies is seen at age 9, leading a profound loss at all 
frequencies in the third decade.  
PID IV-7 - Proband 
• Onset can’t be determined. We have audio data from the second, third and fifth decade. 
In the right ear, the proband presents with mild sloping to profound hearing loss in the 
second and third decade. In the fifth decade, the hearing phenotype progresses to a 
moderate sloping to profound loss. In the left ear, the proband presents with a mild 
sloping to profound hearing loss in the second decade. However, there appears to be a 
lack of symmetry between the right and left ears in the third and fifth decade, as the 
subject progresses to a moderately severe/profound loss at all frequencies.   
PID V-6 
• Hearing loss in this subject is likely congenital, as we have an audiogram from at one 
year of age, presenting with a flat, mild/moderate loss in both ears. The exception is the 
8kHz hearing threshold, which is in the profound range. At age 5, subject presents with 
a mild loss at 0.25 and 0.50 kHz, dipping down into moderate at 1 kHz and back into 
mild thresholds at the 2, 3 and 4 kHz frequencies. At age 7 and 9, subject presents with 
moderate hearing loss at the lower frequencies, sloping to moderately severe/profound 
in the mid frequencies and back up into the moderate/moderately severe ranges in the 
high frequencies. At ages 13 and 16, subject presents with moderately severe hearing 
thresholds, sloping to profound in the mid frequencies. Higher frequency hearing 
thresholds come back into the moderately sever range at age 13 and exhibit further 
deterioration into the profound range by 16 years of age.  
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PID V-7 (NO DNA) 
• Subject has normal hearing thresholds. 
PID IV-9  
• Onset can’t be determined. We have audio data from the third, fourth and sixth decade. 
In the third and fourth decade, subject presents with mild sloping to profound hearing 
loss in the low and high frequencies, respectively. This hearing loss progresses to 
moderately severe sloping to profound in the sixth decade.  
PID IV-10  
• Onset can’t be determined. We only have a single audiogram for this family member. At 
55 years of age, subject presents with moderately severe hearing thresholds at 0.25kHz 
and profound thresholds at other frequencies. 
PID IV-11  
• Onset can’t be determined. We only have a single audiogram for this family member. At 
53 years of age, subject presents unilateral hearing loss. In the right ear, subject has a 20 
dB hearing threshold at 0.25 kHz, which slopes into the moderately severe range at 
higher frequencies. Given that we are dealing with bi-lateral hearing loss, this 
phenotype most likely has nothing to do with the phenotype in question. 
PID V-8  
• Onset can’t be determined. We have audiograms from the first and second decade. This 
family member does not have a DNA sample. At 3 years of age, subject presents with 
normal hearing thresholds at 0.25 and 0.50 kHz, with mild hearing loss at 1 kHz. The 3, 
4, and 6 kHz thresholds come back into the normal range, but deteriorate into the 
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moderate range at 8kHz. At 8 years of age, the same audiogram configuration is present; 
however, the 4 and 6 kHz frequencies drop into the mild hearing loss range in the right 
ear. Relative to the right ear, the left ear seems to have a more significant loss at the 3, 
4, 6, and 8 kHz frequencies, as it slopes from the normal to profound range. At 13, the 
2, 3, 4, 6 and 8 kHz a marked deterioration and begins to resemble a mild, sloping to 
moderately severe (right ear) and mild sloping to profound (left ear) configuration.  
PID V-9  
• Onset can’t be determined. We only have a single audiogram for this family member. At 
16 years of age, subject presents with normal low frequency (0.25 and 0.50 kHz) 
hearing thresholds that slope into the profound range. Even though it’s very unlikely 
that this hearing loss is due to CLDN14, this audiogram reminded of the R2010 family.  
PID V-12 
• Onset can’t be determined. We have audiograms from the third, fourth and fifth decade. 
At 21 years of age, the right ear exhibits profound hearing threshold at all frequencies, 
while the left ear 0.25 kHz and 0.50 kHz hearing thresholds are in the moderate and 
moderately severe ranges, respectively. In the fourth and fifth decade, all hearing 
thresholds are in the profound range.  
PID IV-14  
• Onset can’t be determined. We have audiograms from the fourth, fifth and sixth decade. 
In the fourth decade, this family member presents with a moderate, sloping to profound 
hearing loss. While this does slope, it doesn’t look like hearing thresholds deteriorate as 
aggressively from low to high frequencies, when compared to other family members. 
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While all left ear hearing threshold are in the profound range in the fifth and sixth 
decade, lower frequencies in the right ear are in the moderately sever range in the fifth 
decade. 
PID V-12  
• Onset can’t be determined. We only have a single audiogram for this family member. At 
27 years of age, subject presents with normal, sloping to moderately severe hearing loss.  
This appears to be a more mild bilateral loss. I think it’s interesting to point out that her 
audiogram configuration resembles the right ear of 2070.0028 (AM15-17), a married-in, 
consanguineous family member with unilateral hearing loss.  
PID V-10  
• Onset can’t be determined. We have audiograms from the second and third decade. At 
15 years of age, subject presents normal/borderline hearing thresholds from 0.25 to 4 
kHz, while the 6 and 8 kHz frequencies are in the moderate and moderately severe 
ranges in the right and left ear, respectively. At 26, her hearing thresholds are 
normal/borderline from 0.25 to 1.5 kHz, but further deterioration is apparent at the 2, 3, 
4, 6 and 8 kHz frequencies, sloping from mild to moderate hearing loss. Perhaps this is 
an earlier stage of her sister, 2070.A017 (KR15-14)? 
PID V-13  
• Subject has normal hearing thresholds at 19 years old. 
PID IV-17  
• Subject has mild/borderline hearing loss at the 2, 3, 4, 6 and 8 kHz frequencies. Given 
that she is 58 years old at the time of testing, this is most likely a case of presbycusis. 
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Despite the likelihood of presbycusis, an important question is yet to be determined “Is 
presbycusis an age-related deterioration, or is it due to complex inherited genetics?” – 
Food for thought.  
PID III-7 
• Onset can’t be determined, as we only have a single audiogram on file. At 70 years of 
age, subject has profound, flat hearing loss on all frequencies.  
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